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In general it is thought that children with AD/HD have lower IQs than non-
affected children. However, the variability in research findings has made it difficult to 
reach an accurate conclusion regarding the intellectual functioning of children with 
AD/HD. A primary reason for such inconsistencies appears to be the failure to assess the 
effects of stimulant medication on test performance. The current study investigated 
whether changes occur in the WISC-IV test scores of children with AD/HD as a function 
of stimulant medication usage. Thirty-five male and female children who were diagnosed 
with AD/HD and taking stimulant medication to treat their symptoms participated in the 
study. A within-subjects design was used whereby all children were tested on two 
occasions with a split-half version of the WISC-IV. Children were randomly assigned to 
be on medication for one testing session and off medication for the other session. As 
expected, medication usage improved scores on the FSIQ, with an average increase of 
seven points. This increase in scores appeared to be driven by improved performance on 
several indices including the Working Memory Index (WMI), Processing Speed Index 
(PSI), and Verbal Comprehension Index (VCI), with the largest increase seen on the 
WMI. Children identified as having a positive response to their medication showed the 
largest improvements on IQ scores. This study provides evidence that children with 
AD/HD do not necessarily have lower IQs than unaffected children. Implications for the 
assessment and treatment of children with AD/HD were discussed. 
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CHAPTER I 
INTRODUCTION 
 
 
Attention Deficit/Hyperactivity Disorder (AD/HD) is one of the most common 
psychiatric disorders in childhood, with an estimated incidence of 3-5% (American 
Psychiatric Association, 2000). It is a disorder characterized by developmentally 
inappropriate levels of inattention, hyperactivity and/or impulsivity. Contemporary 
models of AD/HD link the core symptoms of the disorder to deficits in the prefrontal 
lobes (Nigg, 2006). Specifically, research has identified functional abnormalities and 
reduced brain volume in the frontal cortex, basal ganglia, and cerebellar structures as well 
as problems with catecholamine neurotransmission as pathophysiological mechanisms in 
AD/HD (for reviews, Barkley, 2006; Faraone et al., 1999). These areas of the brain are 
believed to be responsible for executive functions (EFs), the capacities that allow 
individuals to generate voluntary behaviors that are controlled and actively guided 
(Slattery, Garvey, & Swedo, 2001). The impulsivity and inattention that is common in 
AD/HD suggest deficits in the voluntary control of behavior. In recent years it has been 
argued that a core deficit in behavioral inhibition underpins the symptoms of the disorder 
(Barkley, 2006). This lack of inhibition is believed to disrupt the efficacy of several EFs, 
causing children with AD/HD to act impulsively and give little thought to the 
consequences or the appropriateness of their behavior, while also having difficulty 
sustaining attention and completing tasks.  
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As a result of poor behavioral inhibition, children with AD/HD often exhibit 
difficulties in numerous domains of daily functioning. A large body of literature has 
identified numerous consequences that AD/HD has on a child’s ability to learn and make 
progress in school. Previous studies show that children with AD/HD have a higher 
incidence of grade retention, poor school performance, and an increased number of 
school suspensions and expulsions (Barkley, 2006, Forness & Kavale, 2001). 
Furthermore, studies have shown that up to 80% of children with AD/HD exhibit learning 
and/or achievement problems (Hoza, Pelham, Dobbs, Owens, & Pillow, 2002; Mayes & 
Calhoun, 2007; Pastor & Reuben, 2002, Semrud-Clikeman, et al., 2000; Tannock, 
Martinussen, & Frijters, 2000). In the realm of social functioning, affected children often 
experience poor peer and family relations, appear less mature compared to their same age 
peers, and experience high rates of peer rejection (Blachman & Hinshaw, 2002; Nixon, 
2001). Children with AD/HD also exhibit problems with motor coordination (Carte, 
Nigg, & Hinshaw, 1996; Karatekin, Markiewicz, & Siegel, 2003; Mariani & Barkley, 
1997; Piek, Pitcher, & Hay, 1999), exhibit poor handwriting, and are more likely to have 
speech problems (Pitcher, Piek, & Barrett, 2002; Raggio, 1999), compared to children 
without the disorder.  
Academic performance is one of the most frequently affected areas of 
functioning. Reasons for this impairment are not entirely clear. Some assume such 
impairment is the direct result of the symptoms of the disorder on a child’s ability to 
learn. Others have suggested these difficulties occur due to the impact of the disorder on 
intellectual functioning. Specifically, some researchers have proposed that as a 
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consequence of inefficiencies in executive functioning, children with AD/HD have lower 
intellectual functioning than those without the disorder (Barkley, 2006). However, this 
notion has generated controversy due to the variability in findings. For instance, Barkley 
(1998) has suggested that children with AD/HD score an average of 7 to15 points lower 
on IQ tests than non-affected children, while others have found that the IQs of children 
with AD/HD are normally distributed, like those of non-affected children (Carlson, 
Mann, & Alexander, 2000; Kaplan, Crawford, Dewey, & Fisher, 2000; Ozonoff & 
Jensen, 1999). Such variability in findings makes it difficult to draw accurate conclusions 
regarding the intellectual functioning of individuals with AD/HD. 
A suspected reason for the differences in IQ scores across studies is the variability 
in the methodologies used. Specifically, the use of poorly defined diagnostic criteria, 
inappropriate subject selection, and the use of varying short forms of IQ tests to assess 
intellectual functioning have created confusing findings regarding the IQs of children 
with AD/HD. One of the most glaring problems noted is the lack of attention paid to the 
impact of treatment on the cognitive performance of children with AD/HD. Although 
stimulant medication is considered the most effective treatment in reducing the core 
symptoms of AD/HD (MTA Cooperative Group, 2006), little research has been 
conducted to determine whether the effects of stimulant medication treatment translate 
into positive changes in IQ scores. The studies that have addressed this topic are 
characterized by methodological problems such as neglecting to monitor whether 
children had taken stimulant medication prior to testing or failure to measure medication 
efficacy prior to testing. Furthermore, most studies look exclusively at group differences 
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by comparing children with AD/HD to unaffected children rather than assessing for 
individual differences. This seems to be an oversight as no specific medication or dosage 
level exists as the universal treatment for AD/HD. Such methodological limitations make 
it difficult to establish a clear relationship between AD/HD and intellectual functioning.  
In light of these circumstances, the objective of the present study was to 
investigate the effects of stimulant medication on the intellectual test performance of 
children with AD/HD. By assessing both group and individual differences in children 
with rigorously defined AD/HD, and by using sound methodological procedures, the 
intent of this study was to help clear up some of the confusion regarding the IQs of 
children with AD/HD. If stimulant medication is shown to improve the test behavior and 
performance of children with AD/HD, it can potentially impact the way in which 
intellectual and achievement assessments are conducted both in clinical and school 
settings. Moreover, related research with children with AD/HD may need to be altered.  
As background for this study, this paper will begin with an overview of AD/HD, 
followed by an explanation of a prominent theory of AD/HD and a discussion of the core 
deficit in AD/HD and the secondary effects on the executive functions and motor control. 
Subsequently, a description of our current knowledge regarding intelligence, the most 
prominent theories of intelligence and the measurement of intelligence will be provided. 
A critical review of the literature on AD/HD as it relates to intellectual functioning is also 
included. The focus will then be directed to a discussion of the relevant literature 
regarding stimulant medications and their effects on AD/HD and intellectual functioning.  
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AD/HD: An Overview 
Diagnostic Criteria  
  The Diagnostic and Statistical Manual-Fourth Edition (DSM-IV; APA, 2000) 
requires several criteria be met to establish a diagnosis of AD/HD. The first criterion 
requires the presence of at least six out of nine symptoms of inattention and/or six out of 
nine symptoms of hyperactivity-impulsivity that are inconsistent with an individual’s 
developmental level. The inattention symptoms include behaviors like difficulty 
following through on tasks, distractibility, and forgetfulness. The hyperactivity symptoms 
include behaviors like fidgeting, being “on the go,” and excessive talking. The 
impulsivity symptoms include blurting out, difficulty awaiting one’s turn, and 
interrupting others. Additional criteria include symptom onset before seven years of age, 
evidence of significant functional impairment in two or more settings, and duration of 
symptoms lasting at least six months. Symptoms that occur exclusively during the course 
of a Pervasive Developmental Disorder or that are better accounted for by another mental 
disorder do not count toward the diagnosis of AD/HD.  
 Within this triad of symptoms, three main subtypes of AD/HD exist, 1) AD/HD, 
Combined Type (C), 2) AD/HD, Predominantly Inattentive Type (IA) and 3) AD/HD, 
Predominantly Hyperactive-Impulsive Type (H-I). Each subtype is diagnosed depending 
on the prevalence of specific symptoms. AD/HD-C is diagnosed when at least six of nine 
inattentive symptoms and six of nine hyperactive-impulsive symptoms are endorsed. 
AD/HD-IA is diagnosed when at least six of nine inattentive symptoms, but fewer than 
six hyperactive-impulsive symptoms are exhibited. Finally, AD/HD-H-I occurs when at 
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least six of nine hyperactive-impulsive symptoms and five or less inattentive symptoms 
are present. The Combined Type is the most common, occurring in 61% of identified 
cases compared to 30% for IA and 9% for H-I (Faraone, Biederman, & Weber, 1998). 
Comorbidity 
Children with AD/HD have high rates of comorbid psychiatric and learning 
problems. In particular, children with AD/HD are often diagnosed with other disruptive 
behavior problems such as Oppositional Defiant Disorder (ODD) and Conduct Disorder 
(CD). Studies have shown that between 32-40% of children with AD/HD have comorbid 
ODD, while 12-30% have comorbid CD (Barkley, 2006). Another 10-40% of children 
with AD/HD have anxiety disorders, with 9-32% having major depression. Elevated rates 
of learning disabilities have also been reported in the child AD/HD population, with 
approximately one-third of affected children exhibiting a learning disability (Barkley, 
1998; Mayes, Calhoun, & Crowell, 2000). 
Barkley’s Theory of AD/HD 
Several models of AD/HD have been proposed, ranging from the idea that the 
disorder stems from generalized deficits in self-regulation (Douglas, 1999), to deficits in 
response inhibition (Quay, 1988), delay aversion (Solanto et al., 2001), or arousal and 
energetic pools (Sergeant & Van der Meere, 1990). Though research continues on the 
merits of these models, many investigators view AD/HD as manifesting impairments in 
inhibitory control (Barkley, 1994, 1997; Nigg, 2006; Schachar, Tannock, Marriott, & 
Logan, 1995). These deficits in behavioral inhibition cause an individual to have 
difficulty inhibiting or delaying responses. Studies consistently show these impairments 
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are attributed to deficits in the prefrontal regions of the brain (Barkley, 1997; Nigg, 
2006), the same areas of the brain where stimulant medications appear to act. One model 
that seems to synthesize this information is that proposed by Barkley (1997). Specifically, 
he proposed that AD/HD is comprised of a developmental delay in, or acquired 
impairment of, the behavioral inhibition networks of the brain that disrupt self-
regulation—an assertion for which there is substantial research support. 
Barkley’s model hypothesizes that inefficient execution of behavioral inhibition 
has a direct influence on the motor system, and causes secondary impairments in four 
specific executive functions that depend on inhibition to work efficiently (See Figure 1). 
These four functions include working memory (i.e., the capacity to hold a mental 
representation in one’s mind to guide behavior), self-regulation of 
affect/motivation/arousal (i.e., an individual’s ability to motivate themselves to behave), 
internalization of speech (i.e., the self-directed speech individuals engage in to guide their 
behavior), and reconstitution (i.e., taking apart incoming information and then using the 
parts or creating new parts to produce a verbal or behavioral response). AD/HD disrupts 
these functions by impairing the first action required for their efficient operation—
inhibition of responding.  
Behavioral inhibition is believed to play a critical part in the performance of the 
executive functions (EFs) because it provides a delay in responding that sets the stage for 
these functions to take action. In particular, Barkley posits that behavioral inhibition 
provides individuals with three abilities important to executive functioning. These 
include the ability to stop a dominant, habitual response (a pre-potent response) from 
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emerging when they know their interests are better served by suppressing it, the ability to 
stop an ongoing response, and the ability to tolerate interferences, which could disrupt 
ongoing mental processes. When behavioral inhibition is compromised, as in a child with 
AD/HD, the executive functions cannot operate properly, leading to a failure to self-
regulate and impaired motor control, producing the symptoms that constitute AD/HD.  
  Deficits in the processes that control and regulate thought and actions cause 
impairments in planning, decision-making, complex reasoning, problem solving, and 
regulating everyday behavior, which are considered hallmarks of intelligence (Sternberg, 
1988). Furthermore, numerous studies have found moderate to strong relations between 
inhibition, working memory, and intelligence (see Ackerman, Beier, & Boyle, 2005; 
Friedman, Miyake, Corley, et. al., 2005; Salthouse, Atkinson, & Berish, 2003). Thus, it is 
conceivable that AD/HD could have a negative impact on intellectual functioning. 
Treatment of AD/HD 
 Recommendations by the American Academy of Pediatrics (AAP, 2001) for the 
treatment of school-aged children with AD/HD indicate that stimulant medications and/or 
behavior therapy are appropriate and safe treatments for AD/HD. Though many clinicians 
believe a multimodal approach is the best treatment plan for children with AD/HD, most 
children receive only stimulant medication. This seems to occur due to the fact that 
stimulants have been identified as the most effective treatment in reducing the core 
symptoms of AD/HD (Abikoff et al., 2004; MTA Cooperative Group, 2004). Studies 
show that approximately 70-80% of people with AD/HD are positive responders to 
stimulants, meaning their symptoms are effectively treated with the use of a stimulant 
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(Bosco & Robin, 1980: Greenhill, Halperin, & Abikoff, 1999; Lerner & Wigal, 2008; 
Wigal, et al., 1999). Hence, stimulants have become the current mainstay of treatment. 
Currently, there are two classes of stimulants prescribed to treat AD/HD. These 
include amphetamine (AMP; Adderall and Vyvanse) and methylphenidate products 
(MPH; Ritalin, Metadate CD, and Concerta), with MPH products being the most 
frequently prescribed (Greenhill, Halperin, & Abikoff, 1999, MTA Cooperative Group, 
2004). Though the mechanism of action of stimulants is not completely understood, it is 
believed they facilitate the uptake and release of neurotransmitters in the prefrontal cortex 
(PFC; Arnsten & Li, 2005; Arnsten, Scahill, & Findling, 2007; Pliszka, 2005). For 
instance, MPH is believed to be involved in the uptake and release of dopamine, a 
neurotransmitter associated with motivation and reward (Volkow, et al., 2001). By 
increasing the amount of dopamine available, individuals are capable of maintaining 
attention and motivation during uninteresting tasks. 
Research regarding the immediate effects of stimulants has shown that children 
who respond favorably to medication exhibit decreases in activities such as talking, 
fidgeting, and engaging in off-task behaviors following the administration of stimulant 
medication (DuPaul & Rapport, 1993; Konrad, Gunther, Heinzel-Gutenbrunner, & 
Herpertz-Dahlmann, 2005). Numerous studies examining performance on measures of 
inattention and impulsivity such as continuous performance tasks (CPT) consistently 
show CPT performance improves following methylphenidate administration (Losier, 
McGrath, & Klein, 1996; Nigg, Hinshaw, & Halperin, 1996; Riccio, Waldrop, Reynolds, 
& Lowe, 2001). In fact, studies have shown that following a dose of stimulant medication 
 10 
children with AD/HD exhibit significant decreases in commission and omission errors 
and improved reaction times (MTA Cooperative Group, 2006; Riccio et al., 2001).  
Although less is known about the effects of stimulants on cognitive processes, 
they are believed to enhance the executive functioning of children with AD/HD (Barnett, 
et al., 2001; Berman, Douglas, & Barr, 1999; Mehta, Goodyer, & Sahakian, 2004; 
Rapport & Kelly, 1991). Stimulants have been shown to improve underlying cognitive 
difficulties in tasks dependent on intact fronto-striatal structures. Mehta et al. (2004) 
found that following a dose of stimulant medication, children with AD/HD demonstrated 
significant improvements in performance on tasks of working memory, visual search, and 
attentional-set shifting. Similarly, Kempton, et al. (1999) found that affected children 
taking stimulant medication exhibited improved performance on the executive functions 
of spatial short-term memory, spatial working memory, set-shifting ability, and planning 
ability in comparison to un-medicated affected children. Thus, the evidence suggests that 
stimulants are associated with better executive functioning.  
Despite the fact that these studies have identified important differences in 
performance when on and off medication, many of these studies focused on differences 
between groups rather than assessing for individual differences. These kinds of analyses 
mask significant variations between individuals. This information is important to 
consider given there are large individual differences in response to medications and doses 
(Chacko, et al., 2005; Chronis, et al., 2001; Swanson, et al., 1998). Studies have also 
identified significant medication dosage effects on CPT performance (Nigg, et al., 1996; 
Sunohara, Malone, Rovet, et al., 1999). Such findings highlight the need to identify the 
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optimal dosage for a given individual. Otherwise, these studies are somewhat limited in 
their generalizability.  
Though stimulant medication is considered the most effective treatment for 
AD/HD, little research has been conducted to determine whether treatment with 
stimulants translates into positive changes in IQ scores. Nonetheless, it is often assumed 
that cognitive performance is enhanced, given that the medication works to alleviate the 
symptoms of the disorder (MTA Cooperative Group, 2004). Therefore, it is reasonable to 
speculate that if stimulant medication improves executive functioning, this should result 
in improvements in IQ test performance.  
Intelligence 
  Throughout history, theorists have tried to demystify the construct of intelligence 
by attempting to define it and develop tests that could measure it. As a result, the 
definition has evolved from simplistic notions such as ‘intelligence is what intelligence 
tests measures,’ to ones based on theoretical ideas. Additionally, intelligence tests have 
developed from crude measures of reaction time into complex batteries assessing 
multiple domains of abilities. Thus, to understand our current conceptualization of human 
intelligence, it is first necessary to describe the theories of intelligence, and then discuss 
how these theories have influenced the development of intelligence tests. 
Theories of Intelligence 
Theories of intelligence are abundant, with each taking a different approach to 
answering the same question. Is intelligence one thing or many things? One of the first 
people to address this question was Spearman (1927), who proposed that intelligence was 
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one general ability, labeled g, that represents what is general or common to all the 
abilities that constitute so-called IQ (intelligence quotient). From his research using factor 
analytic strategies, Spearman identified that numerous cognitive abilities were 
intercorrelated, which implied that intelligence was a single factor.  
 Although Spearman’s introduction of factor analytic techniques was a breakthrough 
in the field, support for a broader conceptualization of intelligence stems both from 
modern theories and research on intelligence. Horn and Cattell’s theory of Fluid and 
Crystallized Intelligences (1966), for example, has broader notions of the abilities 
constituting intelligence than Spearman’s hypothesis. In their original theory, Horn and 
Cattell (1966) postulated that intelligence was not the single construct g, instead it was 
composed of two broad factors called fluid intelligence (Gf) and crystallized intelligence 
(Gc) that were supported by many specific factors called primary abilities. 
 Horn and Cattell (1966) viewed fluid intelligence as a biologically influenced 
dimension of g that decreases over the course of life. This form of intelligence is more 
dependent on physiological structures that support intellectual behavior. Thus, as a 
person ages, these structures begin to deteriorate, thereby explaining why, according to 
this theory, intelligence begins to decrease over time. Fluid intelligence is best measured 
by tasks that require adaptation to new situations, and those for which prior learning is 
not helpful. Therefore, tests of fluid intelligence tend to require more concentration, 
abstract reasoning skills, problem solving, and perceptual speed.  
 Crystallized intelligence is influenced by education and experience, and does not 
decline with age. Instead, it is believed to increase with age as a result of formal and 
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informal educational factors. This form of intelligence is more closely related to factual 
knowledge and acquired skills. It is best measured by assessing an individual’s ability to 
solve problems using information learned as a result of education and cultural 
experiences. Tests of verbal ability, like vocabulary and arithmetic, are measures of 
crystallized intelligence. These tests appear to tap retrieval processes and the application 
of general knowledge abilities.  
As with most constructs, ongoing research has resulted in changes to Horn and 
Cattell’s original theory. For instance, Carroll (1993) built on the Gf-Gc model by 
proposing that intelligence is hierarchical in nature, with three strata of cognitive abilities. 
Current research has identified that an amalgam of the Cattell and Horn’s Gf-Gc theory 
(Horn & Noll, 1997) and Carroll’s three-stratum theory (Carroll, 1993, 1997), called 
Cattell-Horn-Carroll (CHC) Theory of Cognitive Abilities (McGrew & Flanagan, 1998), 
is the most viable psychometric theoretical model of human cognitive abilities (Daniel, 
2000; Snow, 1998; Sternberg & Kaufman, 1998) available to date. This theory was the 
result of factor analytic research, which suggests that g does exist and that this construct 
contains numerous cognitive abilities that vary by degree of breadth. Thus, CHC theory 
blends Carroll’s theory with Horn and Cattell’s Gf-Gc theory by proposing that 
intelligence is composed of three strata—general intelligence or g (stratum III), which is 
composed of 9 broad cognitive abilities (stratum II; see Table 1 for a description) that are 
composed of 70 narrow cognitive abilities (stratum I; see Figure 2). Although theories 
such as the aforementioned have largely been divorced from the development of 
measures to assess intelligence, many of the intelligence tests used today incorporate 
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elements of CHC theory into their structure. 
Measurement of Intelligence: The WISC-IV 
The vast enterprise of modern testing evolved from psychologists’ pioneer work 
to measure general intelligence or g. One of the first IQ tests developed to measure g was 
the Binet-Simon scale (1905), which was later revised by Binet and Terman (1916) and 
became known as the Stanford-Binet. The Stanford Binet became the standard of 
comparison for subsequent IQ tests due to its introduction of the “intelligence quotient” 
scoring scheme, which made it possible to compare the scores of children of different 
ages. Today, there are over 2,600 published psychological assessment measures designed 
to assess a diverse array of mental abilities. However, the most well-known and utilized 
IQ tests are the Wechsler scales. Over the past five decades, psychologists have 
overwhelmingly relied on the Wechsler scales to make decisions about special education 
services and programming issues (Esters, Ittenbach, & Han, 1997; Wilson & Reschly, 
1996).  
The current version of the Wechsler scales used to assess the intellectual ability of 
children is the Wechsler Intelligence Scale for Children – Fourth Edition (WISC-IV; 
Wechsler, 2003). The WISC-IV was developed in 2003 and includes many of the same 
features as its predecessor, the WISC-III (Wechsler, 1991). It is used to measure the 
intellectual abilities of children 6 to 16 years of age, and was standardized on 2,200 
children who were selected to match the 2002 U.S. Census data. It is extremely reliable 
with internal consistency reliability coefficients of .72 or above for all age ranges covered 
by the test. Consistent with the CHC theory, the WISC-IV is composed of three strata: 
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subtests (narrow cognitive abilities), indices (broad cognitive abilities), and FSIQ (g). 
However, it is important to note that not all of the abilities proposed as part of CHC 
theory are assessed by the WISC-IV. 
Subtests 
The WISC-IV has a total of 15 subtests (10 core subtests and 5 supplemental 
subtests), each of which represent the most specific measures of intellectual abilities such 
as spatial relations, perceptual speed, and visual memory. The 10 core subtests are 
Similarities, Vocabulary, Comprehension, Block Design, Picture Concepts, Matrix 
Reasoning, Digit Span, Letter-Number Sequencing, Coding, and Symbol Search. The 
five supplementary subtests are Information, Work Reasoning, Picture Completion, 
Arithmetic, and Cancellation. Descriptions of the subtests and their CHC classifications 
are provided in Table 2. As seen in Figure 3, each subtest loads on one of four indices.  
Indices 
As a result of factor analysis, four indices were identified as the best model to 
describe the WISC-IV. Consequently, the VIQ and PIQ scales from the WISC-III were 
dropped and several indices were restructured and renamed to accurately reflect the 
constructs they measure. The Freedom From Distractibility factor was replaced with the 
Working Memory Index (WMI), and the Perceptual Organization Index was renamed the 
Perceptual Reasoning Index (PRI). The WISC-IV indices are the Verbal Comprehension 
Index (VCI), Perceptual Reasoning Index (PRI), Working Memory Index (WMI), and the 
Processing Speed Index (PSI). The following is a description of each of the indices.  
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Verbal Comprehension Index (VCI). The VCI is comprised of five primary 
subtests (Similarities, Vocabulary, Comprehension, Information, and Word Reasoning) 
and two supplementary subtests (Information and Word Reasoning). This factor provides 
valuable information about a child’s crystallized intelligence or Gc. It offers insight into a 
child’s comprehension of verbally presented information, ability to process verbal 
information and think with words, and the application of verbal skills and information to 
the solution of new problems. Children with high scores on this factor often have high 
achievement orientation, demonstrate readiness to master school curriculum, possess 
knowledge of the cultural milieu, and maintain good scholastic aptitude.  
Perceptual Reasoning Index (PRI). This index consists of the Block Design, 
Picture Concepts, and Matrix Reasoning subtests, and the supplementary subtest Picture 
Completion. The PRI was structured to reflect an increased emphasis on fluid reasoning 
abilities (Gf). Thus, the subtests measure a child’s ability to think in terms of visual 
images, and provide insight into a child’s ability to organize and interpret visual 
information and form abstract concepts and relationships without the use of words. 
Factors including a child’s level of alertness, persistence, interests, and visual-motor 
organization can significantly affect performance on these subtests.  
  Working Memory Index (WMI). The subtests of the WMI include Digit Span, 
Letter-Number Sequencing, and the supplemental subtest Arithmetic. This index provides 
information regarding the broad ability of short-term memory (Gsm). The subtests assess 
a child’s ability to hold information in mind temporarily and to perform some operation 
or manipulation with the information, all while filtering out distractions in order to 
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produce a correct result. The WMI subtests require children to hold numbers or letters, 
presented either visually or orally, in mind in order to act on this information. The WMI 
also offers information regarding a child’s numerical and encoding abilities, use of 
rehearsal strategies, flexibility in performing mental operations, and ability to self-
monitor. Children with low scores on this index often have difficulty rapidly shifting 
mental operations on symbolic material, and are easily distracted.   
Processing Speed Index (PSI). This index includes the Coding and Symbol Search 
subtests and the supplemental subtest Cancellation. It is considered a measure of an 
individual’s cognitive processing speed (Gs), the speed at which an individual can 
process incoming information. Each subtest is timed in order to capture the speed at 
which an individual completes basic cognitive functions, such as simple discriminations 
or item identification. The PSI also provides information about a child’s psychomotor 
speed, short-term visual memory, cognitive flexibility, and level of concentration. 
Children who have difficulties on these subtests often exhibit poor motivation, anxiety, 
problems working under time pressure, visual defects, distractibility, impulsivity, and 
deficient concentration skills.  
FSIQ 
The Full Scale IQ (FSIQ) is considered the best measure of general intellectual 
ability. It measures general intelligence, scholastic aptitude, and readiness to master a 
school curriculum (Sattler, 2001). The FSIQ score is derived from the 10 core subtests 
included in the four indices. This is a significant change from the WISC-III, where the 
sum of the verbal and performance IQ scores was used to obtain the FSIQ. This change 
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means that the FSIQ now includes greater contributions from working memory and 
information processing speed. Accordingly, FSIQ scores are often affected by a child’s 
level of motivation, interests, neurological integrity, attention span, ability to process 
verbal information, ability to process visual information, and psychomotor ability.  
Application of IQ Theory and Measurement to AD/HD 
  Given the overlap between the abilities assessed by IQ tests and those proposed 
by Barkley to be affected by AD/HD, it is reasonable to speculate that children with 
AD/HD might exhibit lower levels of intellectual functioning. For instance, working 
memory, which is assessed by the WISC-IV, is an ability affected by the lack of 
behavioral inhibition in children with AD/HD. Consequently, affected children would be 
expected to perform poorly on working memory tasks, resulting in lower WMI scores. 
Moreover, since the WMI score is included in the calculation of the FSIQ score, as 
proposed by CHC theory, one can assume that a low WMI would result in a lower FSIQ 
score. Although these are rather logical propositions, the literature reveals mixed results, 
especially in regards to the FSIQ scores of children with AD/HD. A review of the 
literature will be helpful in elucidating this point. Since the WISC-IV is relatively new, 
and little research has been conducted with this measure, this review will focus primarily 
on findings from studies of the WISC-III. 
WISC Index Scores and AD/HD 
  Few studies have assessed between-groups differences in WISC-III index scores, 
especially in regards to the Verbal Comprehension Index (VCI) and the Perceptual 
Organization Index (POI; similar to WISC-IV PRI). In fact, no studies were found that 
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addressed differences in the VCI and POI scores of children with AD/HD. Instead, the 
majority of studies focus on whether affected children exhibit lower Processing Speed 
Index (PSI) and Freedom From Distractibility (FFD; similar to WISC-IV WMI) scores 
than non-affected children. The results of these studies suggest that these scores are lower 
for children with AD/HD. This is not surprising considering the types of deficits children 
with AD/HD face as a result of poor behavioral inhibition and impaired executive 
functioning. What is surprising is the amount of variability seen across studies in the size 
of the score differences. 
WMI and AD/HD 
 Various investigations have shown that a substantial relationship exists between 
working memory and intelligence. Using structural equation modeling, Engle, Tuholski, 
Laughlin, and Conway (1999) found a considerable link between intelligence and 
working memory. However, Engle and Kane (2004) proposed that the relationship 
between working memory and general fluid intelligence was mediated by attentional 
control. Thus, the ability to maintain attention, even in the event of distraction, plays an 
important role in an individual’s ability to hold information in an active and easily 
accessible state. As a result, children with higher levels of inattention would be expected 
to receive lower scores on IQ tests that measure working memory and fluid intelligence.  
  Studies of children with AD/HD appear to support this finding. Although no 
studies exist that address the relationship between AD/HD and the WMI, studies 
assessing the relationship between AD/HD and the WISC-III Freedom From 
Distractibility (FFD) factor, the predecessor to the WMI, were identified. In particular, 
 20 
several studies found that children with AD/HD score significantly lower on the FFD 
than children without the disorder (Hinshaw, 2002; Rucklidge & Tannock, 2001; Snow & 
Sapp, 2000; Toplak, et al., 2003). Hence, tasks that put a premium on retaining a 
representation in an active and easily accessible state prove difficult for children with 
AD/HD. Therefore, preliminary evidence suggests that AD/HD affects performance on 
the FFD, which should translate into lower scores on the WMI. Nonetheless, the 
variability in scores across studies suggests these findings may not be accurate. For 
instance, in the Toplak et al. (2003) study only preadolescent girls with AD/HD and a 
comorbid reading disorder exhibited significant differences in FFD scores compared to 
controls. Girls with only AD/HD did not exhibit significant differences on the FFD in 
comparison to non-affected girls. These disparities potentially resulted from the tendency 
for group-based analyses to conceal critical individual differences. A study by 
Anastopoulos, Spisto, and Maher (1994) highlighted this by conducting both group and 
individual-based analyses to study the FFD of children with AD/HD. Their results 
indicated that at a group level, affected children obtained lower FFD scores compared to 
their scores on the VCI and POI. However, when individual level analyses were 
conducted, a substantial number of affected children did not exhibit this same pattern of 
differences. Such findings emphasize the importance of conducting both group and 
individual level analyses when assessing the test performance of children with AD/HD.  
PSI and AD/HD 
  The subtests of the PSI place a premium on speed within a timed context. Barkley 
(1997) has proposed that individuals with AD/HD have a poor subjective sense of time 
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due to working memory deficits that make it difficult to hold sequences of events in mind 
and to make comparisons among them. This suggests that children with AD/HD would 
score lower on the PSI than those without the disorder. Several studies have found that 
scores on the PSI are significantly lower for children with AD/HD compared to 
unaffected children (Hinshaw, 2002; Rucklidge & Tannock, 2001; Snow & Sapp, 2000; 
Toplak, et al., 2003). However, the findings vary across studies, with PSI scores ranging 
from 6 to 19 points lower.  
  Although these findings indicate that AD/HD has a negative impact on an affected 
child’s performance on the PSI subtests, the variability across studies suggests the actual 
effect of AD/HD on a child’s processing speed is not being adequately measured. This 
may be the result of different methodologies used in these studies. In particular, some of 
the studies looked at gender differences, while others grouped both genders or studied 
only one gender. For example, Hinshaw (2002) investigated differences in the IQ scores 
of preadolescent females, while Rucklidge and Tannock (2001) looked at the differences 
in males and females with AD/HD. In the study by Rucklidge and Tannock (2001) males 
with AD/HD scored approximately 10 points lower on the PSI compared to females with 
AD/HD. Thus, gender differences in the IQ scores of children with AD/HD may exist, 
which could affect the results. Another interesting finding comes from Toplak et al. 
(2003). Here, two studies were conducted; the first was to compare differences between 
children with AD/HD and those with AD/HD and a reading disability. The second looked 
at differences between these groups and healthy controls. Oddly, in the first study the 
mean PSI score for children with AD/HD aged 6-11 was 107, whereas in the second 
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study, which used a sample of children aged 13-16, the mean PSI score was 99. This 
difference suggests that age may also play a role in the findings regarding AD/HD and 
IQ. Though these studies bring to light the importance of studying group differences such 
as age and gender, neither looked at the role of individual differences and the impact this 
could have on the findings. 
WISC FSIQ Score and AD/HD 
  Sixteen studies were identified that assessed differences in WISC-III FSIQ scores 
of children with and without AD/HD. Of these, the majority (10 studies) suggests that 
children with AD/HD score anywhere between 7 to 12 points lower on measures of 
intelligence than the general population (Beebe, Pfiffner, & McBurnett, 2000; Frazier, 
Demaree, & Youngstrom, 2004; Hinshaw, Carte, Sami, Treuting, & Zupan, 2002; Lorch, 
et al., 2004; Kuntsi, Oosterlaan, & Stevenson, 2001; Rucklidge & Tannock, 2001; Tripp 
& Alsop, 2001; Tripp, Ryan, & Peace, 2002; Toplak, et al., 2003; Wu, Anderson, & 
Castiello, 2002). Although these findings seem convincing, they must be interpreted with 
caution due to the variance in methodologies used to reach these conclusions, and the 
failure to consider the effects of possible confounds. In particular, only four of these 
studies used the DSM-IV criteria to diagnosis AD/HD, administered the WISC-III in its 
entirety to obtain FSIQ, and identified the medication status of children with AD/HD 
prior to testing. Given that the diagnosis of AD/HD has changed greatly over the years, it 
seems the use of other criteria may cause variable findings. Additionally, Sattler (2001) 
has warned against using only a few subtests to estimate FSIQ, given these estimates 
often yield erroneous classifications. It also seems imperative that studies assess whether 
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participants are on or off medication during the time of testing. This is important not only 
to ensure that the groups being studied are equivalent, but also because individuals being 
treated with medication may perform better as a result of treatment.  
  Interestingly, one of the 16 studies was a meta-analysis of 123 studies from 1980 
to 2002 (Frazier, et al., 2004). The results indicated the overall cognitive ability of 
children with AD/HD was approximately 9 points lower than those without the disorder 
(weighted mean effect size of .61). This finding is complimentary to the proposal by 
several theorists that the difference between children diagnosed with AD/HD and 
comparison children should be around 7 to 12 IQ points (Crosbie & Schachar, 2001; 
Mariani & Barkley, 1997; Rucklidge & Tannock, 2001). However, many of the studies 
included in the analysis lack sound methodologies, making it difficult to assess the 
specific impact AD/HD has on intellectual functioning. In particular, although analyses 
were conducted to determine if different methodological variables, such as differences in 
DSM criteria, type of IQ test, and method for estimating overall IQ, influenced the 
findings, other possible confounds were not assessed. Many studies did not control for 
subtyping, few addressed issues of comorbidity, and many used only a 2-4 subtest short 
form of an IQ test to assess FSIQ. 
  Upon closer inspection of the six studies with null findings, it was noted that 
methodological limitations were also evident. Specifically, a study by Mayes and 
Calhoun (2002) used controls that were referred for academic problems associated with 
low average IQ, making it difficult to make accurate comparisons. Also, two studies did 
not report medication status during the time of testing (Nigg, 1999; Snow & Sapp, 2000). 
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Other problems included small sample sizes, the use of a 2-subtest WISC-III short form 
to estimate FSIQ, and the inclusion of children with various comorbid diagnoses. 
Interestingly, one study actually suggested that the IQs of children with AD/HD are 
normally distributed, basing this information on a 2-subtest WISC-III short-form that 
used WISC-R norms to calculate the FSIQ (Kaplan, et al., 2000).   
   According to the WISC-IV special group studies, children with AD/HD were 
found to score significantly lower on the WMI, PSI, and FSIQ compared to children 
without the disorder (Wechsler, 2003). In fact, a moderate effect size for the group mean 
difference was found for the PSI, while small effect sizes were noted for the VCI, WMI, 
and FSIQ. These results indicated that children with AD/HD score approximately seven 
points lower on the WISC-IV than unaffected children. Nonetheless, a major weakness 
was observed in this study. Specifically, 64% of children in the AD/HD group were 
taking medication during the time of testing. With over half of the sample receiving 
treatment at the time of testing, it is inappropriate to assume the results are an accurate 
representation of the IQ scores of children with AD/HD.  
Like most areas of research, there are numerous methodological problems with 
which investigators must cope (e.g. problems related to subject selection, design, and 
measurement). Thus, it is no surprise that some of the studies assessing the IQs of 
children with AD/HD exhibit these kinds of problems. However, it is surprising that none 
of these studies assessed the impact of treatment of AD/HD on the intellectual 
functioning of children with AD/HD. Treatments for AD/HD are not only aimed at 
reducing the core symptoms of AD/HD, but also address the fundamental problems of the 
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disorder— poor behavioral inhibition and impaired executive functioning. It seems that a 
failure to consider the effects of treatment on the cognitive functioning of children with 
AD/HD is a major limitation in the AD/HD and IQ literature. Moreover, the lack of 
attention paid to studying individual differences is surprising, especially given findings 
like those from the Anastopoulos et al. (1994) study. 
As previously mentioned, stimulant medications are the most frequently used 
method to treat AD/HD because of their known efficacy in alleviating the symptoms of 
the disorder (MTA Cooperative Group, 1999). Despite this knowledge, the majority of 
the studies included in this review, as well as those in the meta-analysis conducted by 
Frazier et al. (2004), failed to consider the immediate or long-term effects of treatment 
with stimulants on the intellectual functioning of children with AD/HD. In fact, most 
studies failed to report whether the children were on or off medication at the time of 
testing, while others included mixed groups of children, with some children being on 
medication and others not. This seems to be a gross oversight considering stimulant 
medication may affect a child’s performance on an IQ test. Such methodological flaws 
make it difficult to establish a clear relationship between AD/HD and IQ.  
The Effects of Stimulant Medication on IQ 
Despite extensive studies regarding the effects of stimulant medication on 
behavior in AD/HD, few studies have investigated its effects on intelligence test 
performance, especially at the individual level. In fact, most studies addressing this 
relationship were carried out over 25 years ago and were based on group findings, which, 
as mentioned earlier, tend to mask clinically relevant individual differences. Moreover, 
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the findings from these studies are mixed, with some suggesting moderate group 
increases in FSIQ scores (Barkley, 1977; Sandoval, 1977; Whalen & Henker, 1976), 
while others suggest minimal changes in scores that are believed to represent normal 
variance (Finnerty, Soltys, & Cole, 1971; Sykes, Douglas, Weiss, & Minde, 1971; 
Wolraich, 1977). Variability is also evident in the findings regarding the effects of 
stimulants on the Verbal IQ and Performance IQ and the index and subtest scores.  
Like the studies assessing IQ differences in children with AD/HD, inspection of 
the studies on the effects of stimulants on intellectual functioning in children with 
AD/HD reveal numerous methodological differences that may be creating the variability 
in findings. Important among these differences are the criteria used to define AD/HD, the 
attention given to the assessment of intellectual functioning, the ways in which children 
were identified as treatment responders, the design used to assess differences, and the 
difference between immediate and long-term effects of stimulants. Published studies 
include children who met criteria for DSM-III to DSM-IV, as well as those described as 
hyperactive but who do not meet DSM criteria for AD/HD. Methods used to identify if 
children met these diagnostic criteria also vary widely across studies. Several studies did 
not titrate doses of stimulant medication to find the most effective dose for the 
participants, which could affect test performance. Also, many studies make between-
group comparisons to assess the effects of stimulant medication, while others make 
within-group comparisons. Such differences could account for the variability in findings.  
Recent studies that have addressed the relationship between stimulant medication 
and IQ test performance have focused on the long-term effects of medication on IQ 
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scores. Gillberg et al. (1997) found that after 15 months of treatment with a stimulant 
medication, Swedish children exhibited a mean increase of 4.5 points on the WISC-R. A 
more recent investigation found that children with AD/HD demonstrated significant 
improvements in WISC-III IQ scores following 1 year of stimulant medication treatment 
(Gimpel, et al., 2005). Although these findings are promising, these studies were beset by 
methodological issues that may have resulted in flawed findings. Particularly, issues like 
symptom severity, efficacy of stimulant medication treatment, and the effects of other 
treatment methods were neglected.  
In summary, the literature regarding the effects of stimulant medication on IQ test 
performance is inconsistent, with findings varying from large improvements in IQ scores 
to no change in scores. These inconsistencies are possibly due to methodological 
differences across studies. As a result, we do not know whether treatment with stimulant 
medication results in improved IQ scores. 
Summary and Hypotheses 
In general it is thought that children with AD/HD have lower IQs than non-
affected children. However, the wide range of variability in research findings makes it 
difficult to reach an accurate conclusion. A primary reason for such inconsistencies 
appears to be the failure to assess the effects of stimulant medication on test performance. 
Studies have shown that stimulants improve performance on tests of behavioral inhibition 
and executive functioning (Barnett, et al., 2001; Epstein et al., 2003; Kempton, et. al., 
1999; Mehta, et al., 2004; MTA Cooperative Group, 2004). Thus, it is reasonable to 
assume that treatment with stimulant medication would affect a child’s performance on 
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an IQ test.   
The objective of the present study, therefore, was to investigate the effects of 
stimulant medication on the IQ test performance of children with AD/HD. Specifically, 
this study investigated whether changes occur in the WISC-IV test scores of children 
with AD/HD as a function of stimulant medication usage. Based on Barkley’s theory, one 
would expect children with AD/HD to obtain lower scores on the WISC-IV, given its 
inclusion of measures of working memory and processing speed in the calculation of the 
FSIQ score, as implicated by CHC theory. Furthermore, since children have different 
responses to medication, an assessment of both group-based and individual-based 
differences was performed to determine whether group-based findings are applicable to 
individual children. With this in mind, the following hypotheses were made: 
1. Given that stimulant medication has been shown to improve executive functioning, it 
is hypothesized that children with AD/HD will exhibit improved scores on the WISC-
IV FSIQ and index scores when on stimulant medication.  
2. Consistent with prior research and theory, the largest increases would be expected on 
the indices and subtests that measure abilities controlled by executive functions. 
Thus, scores on both the WMI and PSI should increase significantly when compared 
to scores on these indices from the un-medicated session.  
3. Finally, children who are considered positive treatment responders should show the 
greatest improvements in IQ scores compared to children who are taking medication, 
but it is not as effective in treating their symptoms.
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CHAPTER II 
METHOD  
 
 
Participants 
To be eligible for the study, each child met the following criteria for participation: 
(a) chronological age between 8 years 0 months and 14 years 11 months; (b) a diagnosis 
of AD/HD, any type; (c) current use of stimulant medication to treat symptoms of 
AD/HD; and (d) considered a positive responder to stimulant medication treatment. 
Children with the additional diagnoses of oppositional defiant disorder (ODD), conduct 
disorder (CD), or learning disability (LD) were allowed to participate in the study due to 
the high comorbidity of these disorders with AD/HD.  
The diagnosis of AD/HD was established on the basis of parental responses to the 
AD/HD module of the Computerized Diagnostic Interview Schedule for Children (C-
DISC-IV; Shaffer, Fisher, Lucas, et al., 2000), accompanied by clinically significant T-
scores at or above the 93rd percentile on the attention problems and/or hyperactivity 
subscales of the BASC-II or ADHD Rating Scale–IV completed by parents and/or 
teachers. Only children currently taking stimulant medication to treat their AD/HD 
symptoms were allowed to participate in the study. Thus, children taking other forms of 
psychotropic medications were not eligible for participation. Each child’s prescribing 
physician was contacted to verify the prescription information, provide a rating of the 
child’s response to treatment with stimulant medication, and give approval for the child 
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to be off medication for the un-medicated testing session.  
Exclusionary conditions for the study included evidence of psychosis, mental 
retardation, anxiety, depression, head injury, birth trauma or pervasive developmental 
disorders. Evidence of such difficulties was obtained from the BASC-II (completed by 
the child’s primary caregiver and/or teacher), parental responses to the C-DISC-IV, and 
responses to specific questions included on the Participant Information and Demographic 
Questionnaire completed by the child’s primary caregiver. Children with scores > 93rd 
percentile on the Anxiety or Depression subscales of the BASC-II and a diagnosis of a 
mood or anxiety disorder on the C-DISC-IV were excluded from participation. Children 
with an estimated WISC-IV FSIQ score of <70 were also excluded.  
A summary of demographic variables and sample characteristics is presented in 
Table 3. A total of 44 male and female children were recruited from a university-based 
AD/HD clinic to participate in a study on “The effects of stimulant medication on IQ 
scores.” All children had undergone a comprehensive multi-method AD/HD assessment, 
with portions of the assessment data being used to determine eligibility to participate in 
the study. Nine children who began the study dropped out or were found ineligible for 
various reasons including: adding a non-stimulant medication to their medication regimen 
(N = 3), having to stop taking the stimulant due to the development of a tic disorder (1), 
repeatedly missing scheduled testing appointments (2), and no longer meeting diagnostic 
criteria (3).  
The final sample of 35 children consisted of 25 boys with AD/HD and 10 girls 
with AD/HD. The participants’ ages ranged from 8.0 to 14.0 years, with a mean age of 
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10.9 years. Racial backgrounds were slightly different than that observed in the 
community, with 88.6% Caucasian children and 11.4% African-American children 
participating in the study. All three types of AD/HD were represented with 57.1% of 
participants diagnosed with AD/HD-C, 34.3% with AD/HD-IA, and 8.6% with AD/HD-
H-I. Thirty-seven percent of participants were taking Concerta, 25.7% Adderall XR, and 
11.4% Ritalin LA. The remaining 25.7% were taking other kinds of stimulant 
medications like Vvyanse, Daytrana, etc. The average amount of time the children had 
been on their stimulant medication was thirty months. Most children had an 
Individualized Education Plan (IEP) and were receiving special classroom 
accommodations due to their diagnosis; however, the majority of participants had never 
failed a subject, repeated a grade, or been suspended or expelled from school. Rates of 
comorbid diagnoses were also somewhat lower than those seen in the community. In 
particular, 22.9% of children were diagnosed with a Learning Disability, 5.7% were 
diagnosed with ODD, and only 2.9% were diagnosed with CD. These lower rates of 
comorbidity and academic difficulties indicate that the sample may represent a higher 
functioning group of children with AD/HD. 
Measures 
Computerized Diagnostic Interview Schedule for Children. The computerized 
Diagnostic Interview Schedule for Children (C-DISC-IV; Shaffer, Fisher, Lucas, et al., 
2000) is a reliable and valid structured interview designed to assess DSM-IV psychiatric 
disorders and symptoms in children and adolescents 6 to 17 years of age. It includes a 
parent and a child version, both of which ask about the child's psychiatric symptoms. It 
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generates information about symptom counts, age of symptom onset, diagnoses, and 
functional impairment. The items are organized by diagnosis and the responses to most of 
the questions are coded as No (0), Yes (1), Not Applicable (8), or Don't Know (9).  
The C-DISC-IV was administered to each participant’s primary caregiver to 
determine if the child met DSM-IV criteria for a diagnosis of AD/HD and/or other 
psychiatric conditions that may cause the child to be excluded from participation. The 
caregiver was asked if their child exhibited specific symptoms during the past year and 
the past 4 weeks; follow-up questions were asked in the case of positive endorsement. In 
addition to AD/HD, other diagnoses covered as part of this study included: simple and 
social phobia, separation anxiety, panic disorder, conduct disorder, oppositional defiant 
disorder, enuresis, encopresis, tic disorders, major depression, dysthymia, and mania. 
ADHD Rating Scale. The ADHD Rating Scale-IV (ADHD-RS; DuPaul, Power, 
Anastopoulos, & Reid, 1998) is a psychometrically sound instrument for diagnosing 
AD/HD in children and adolescents. There are two versions of the scale, a parent 
questionnaire on home behaviors and a teacher questionnaire on classroom behaviors— 
both of which contain 18 items that are linked directly to DSM-IV diagnostic criteria for 
AD/HD. Each item is rated on a Likert scale from 0-3, ranging from “not at all” to “very 
often.” Both versions consist of a Total Score scale and two subscales, Inattention (nine 
items) and Hyperactivity-Impulsivity (nine items). Only the subscales were used in the 
current study. Raw scores for the subscales were converted to percentile scores by using 
the appropriate scoring profile (presented in the manual) based on the child's gender and 
age. Scoring profiles are available for boys and girls aged 5-17, and are based on 
 33 
nationally representative norms. The two subscale scores were used to provide evidence 
that participants exhibit developmentally deviant symptoms of AD/HD, a criterion 
required for a DSM-IV diagnosis of AD/HD.   
Behavior Assessment System for Children-Second Edition. The Behavior 
Assessment System for Children-Second Edition (BASC-2; Reynolds & Kamphaus, 
2004) is a nationally standardized, normed, and psychometrically sound rating scale that 
uses a multidimensional approach for measuring behavior and emotions of children and 
adolescents. There are several forms of the BASC-2; however, only the Parent Rating 
Scales (BASC-P) and Teacher Rating Scales (BASC-T) for the child (ages 6-11) and 
adolescent (ages 12-21) versions were used in the current study. These forms contain 
100-160 items depending on the age of the child, require a fourth grade reading level, and 
take about 10–20 minutes to complete. Individuals provide ratings of the frequency of the 
child’s behavior on several dimensions of functioning such as externalizing behaviors 
(e.g., conduct problems, aggression, hyperactivity), internalizing problems (e.g., 
depression, anxiety), and adaptive functioning (e.g., social skills). Validity and response 
set indexes are available to help judge the quality of completed forms. A computer 
scoring system generates T scores and percentiles for each dimension based on age and 
gender norms. The scores from the various externalizing and internalizing scales were 
used to assess the developmental deviancy of symptoms, and identify whether other 
conditions exist that may exclude a child from participation in the study. 
Wechsler Intelligence Scale for Children-Fourth Edition. The Wechsler 
Intelligence Scale for Children-Fourth Edition (WISC-IV; Wechsler, 2003) is one of the 
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most widely used measures for assessing the general cognitive ability of children aged 6 
to 16. It includes 10 core and 5 supplemental subtests, all of which demonstrate good 
reliability. All 10 core subtests were administered for the current study. However, 
participants were administered a split-half form of each subtest at each testing session 
rather than entire subtests. The split-half forms of the WISC-IV were created so that form 
A included all odd numbered items on the subtests, while form B used all even numbered 
items.  
Given that the subtests on the Processing Speed Index (PSI) are timed, a split-half 
procedure using odd and even numbered items could not be easily implemented. 
Therefore, alternate forms of the core PSI subtests were created that lend themselves to 
the split-half procedure. For the alternate form of the Coding subtest, the key from the 
original subtest was re-arranged so each number in the key was paired with a different 
symbol (e.g., the 1 was paired with the symbol that was originally paired with the 9 and 
vice versa). This way, the subtest was still able to assess the child’s speed of mental 
operation while reducing the amount of practice effects. For the Symbol Search subtest 
the alternate form involved administering the protocol in reverse order, meaning that the 
child started with the last page of the protocol first and worked toward the first page.  
The process for halving the Block Design and Letter-Number Sequencing subtests 
also had to be modified because the two forms were not equivalent. For Block Design, 
when the subtest was halved the total score on the even form was potentially two points 
higher than the odd form. To make the forms equal, the first item on the odd form was 
scored as a four-point response instead of a 2-point response. For the Letter-Number 
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Sequencing subtest, the odd form was found to be easier than the even form because the 
odd form had two items of the same difficulty level compared to that of the even form, 
where all items administered increased in difficulty. In particular, the odd form went 
from having the child put 2 letters/numbers in correct sequence, to three letters/numbers, 
to another set of three, to a set of five, and then a set of seven. In contrast, the even form 
went from 2 letters/numbers, to three, to four, to six, to eight. Although several ways 
exist to correct this problem, it was decided that for the even form the last item would not 
be administered; instead, the child’s score on the item requiring ordering of three 
letters/numbers would be doubled as if the child had been administered a second set of 
three letters/numbers like that of the odd form. 
Each alternate form of the WISC-IV was scored to provide FSIQ and Index scores 
to be used for comparisons. To accomplish this, raw scores from each subtest on each 
form were doubled to resemble a typical subtest score, had the full subtest been 
administered. These scores were then converted into standard scores based on the child’s 
age. The processes for deriving the FSIQ and Index scores were the same as that 
described in the WISC-IV manual. 
Conners’ Continuous Performance Test. The Conners’ Continuous Performance 
Test (CPT II) Version 5 for Windows (Conners & MHS Staff, 2000) is a reliable and 
valid test that is widely used in AD/HD research and clinical assessments for individuals 
aged 6 or older. The test is administered on a computer and takes approximately 20 
minutes to complete the standard protocol, which includes a practice administration and 
then the full test. The standard protocol uses the short practice exercise prior to the 
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administration of the full test to ensure the respondent understands the task. Participants 
are told that letters of the alphabet will appear on the screen and that they are to press the 
spacebar when any letter except the letter ‘X’ appears on the computer screen.  
Though the CPT II provides numerous measures that assess deficits in attention, 
activation/arousal, and vigilance, only the Error scores, Clinical Confidence Index, Hit 
Reaction Time, Hit Reaction Time Standard Error, and Variability were used in the 
present study. These measures were selected due to their sensitivity to change in children 
with AD/HD following a dose of stimulant medication. In particular, studies show that 
use of stimulant medications generally result in fewer errors of commission and 
omission, as well as decreased reaction times and decreased variability (Conners, 2000). 
The two types of errors analyzed in the CPT include: (1) misses, or omission errors, 
which are considered a measure of inattention; and (2) false alarms, or commission 
errors, which are considered a measure of impulsivity. The Clinical Confidence Index is a 
discriminant function that indicates whether the participant’s overall performance on the 
CPT better matches a clinical versus non-clinical profile. Hit Reaction Time measures the 
mean response time for all target responses, whereas Hit Reaction Time Standard Error is 
the consistency of response times expressed in standard error for responses to target.  
Participant Information and Demographic Questionnaire. This questionnaire was 
created and used in this study to obtain information regarding important variables used in 
determining study eligibility. The child’s primary caregiver completed the questionnaire 
prior to participation in the study. Requested information addressed: the child’s age, 
gender, ethnicity, diagnosis(es), prescribing physician, name of current prescribed 
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medications, prescribing physician’s instructions regarding the medication, length of time 
on current medication, person responsible for administering the medication, whether or 
not the child is responding positively to the medication, and whether or not the family is 
compliant with the physician’s orders regarding medication administration. Parents were 
also asked if their child receives special education services in school, attends remediation 
classes, or receives help from a tutor to determine if the child is learning disabled. 
Questions regarding the child’s mental and emotional status were also asked to assess for 
the presence of other diagnoses such as a pervasive developmental disorder or mental 
retardation. Information regarding history of neurological impairment, closed head injury, 
prenatal or peri-natal birth trauma, chronic physical illness, sensory or motor impairment 
was also obtained. 
Physician Questionnaire. This questionnaire was created and used in this study 
for three purposes; 1) to request approval from the child’s prescribing physician for the 
child to participate in the study, 2) to obtain information regarding the child’s 
diagnosis(es) and medications, and 3) to provide a rating of the efficacy of the child’s 
medication. The medication efficacy question requested the physician to rate how 
effective the child’s medication was on a scale of 1-5, with 1 being “not effective” and 5 
being “extremely effective.” Only children who received an efficacy rating of 3 or higher 
were eligible to participate in the study. 
Procedure 
Participants were recruited from a group of children who had been evaluated by 
the AD/HD Clinic at the University of North Carolina at Greensboro (UNCG). Mothers 
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of children aged 8-14 diagnosed with AD/HD were approached to request their child’s 
participation in a study of the effects of stimulant medication treatment on IQ scores. 
Interested participants were given a detailed description of the study. Parents provided 
written informed consent for their child to participate, and child assent was also obtained 
prior to participation. Parental consent was also obtained to allow the researcher to 
contact the child’s physician to obtain written approval for the child to participate in the 
study. All eligible participants were then assessed using the WISC-IV and CPT on two 
occasions approximately 2-6 weeks apart. The average interval between testing sessions 
was twenty-five days (M = 24.67, SD = 35), with a median of 15 days and a mode of 14. 
Children were randomly assigned to receive their medication prior to the first 
testing session or to be off their medication the day of their first testing session. Efforts 
were made to keep the principal investigator blind to the on/off medication sequence 
assigned to each child by having a research assistant assign and inform the parents of the 
on/off status of the child. The day before testing sessions parents were called by a 
research assistant to be reminded of the child’s on or off medication status. Despite these 
efforts, several accidental disclosures by the child and/or parent did occur (e.g. while 
reading the assent form, one child stated, “But I didn’t take my medicine today.”)   
The testing sessions were conducted by a trained graduate student and lasted 
approximately 60-90 minutes. For the medicated session, parents administered their 
child’s medication at least 90-120 minutes before testing to ensure peak psychostimulant 
medication clinical effect (Gualtieri et al., 1982; Swanson, Kinsbourne, Roberts, & 
Zucker, 1978). For the un-medicated session, children were required to be medication-
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free for the day of testing. Since many children with AD/HD need their medication to 
function appropriately at school, the testing sessions were held on days when this would 
not interfere with school (i.e., Saturday mornings or school holidays). 
For both testing sessions, children completed the CPT and then a split-half form 
of the WISC-IV. The CPT was administered at the start of the sessions to ensure the 
length of time it took to administer the IQ test did not interfere with CPT ratings. The 
order of the split-half forms of the WISC-IV was randomly assigned to reduce the 
possibility of order effects. Once both testing sessions were completed, participants were 
thanked and paid $40 for their participation. The primary caregiver was also mailed a 
summary letter describing their child’s IQ test performance on and off medication. All 
participants were treated in accordance with the American Psychological Association's 
ethical guidelines. 
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CHAPTER III 
RESULTS 
 
 
Preliminary analyses 
An examination of the distributions of each continuous variable, along with 
skewness and kurtosis statistics, indicated all of the variables were approximately 
normally distributed.  
Group Differences. Comparisons to assess for differences between the 
participants who completed the study (completers) and those who did not (non-
completers) were conducted. Independent sample t-tests revealed no differences in age (t 
= 1.97, p = .72), severity of Inattention (t = 1.57, p = .84), severity of Hyperactivity-
Impulsivity (t = .90, p = .67), or length of treatment with medication (t= .61, p = .22). 
Given the small sample size, which resulted in less than 10 children per cell, chi-square 
tests of independence could not be performed. Thus, statistical analyses using Fisher’s 
exact test (FET) were conducted. Results revealed no differences in gender (p = .27, 
FET), race (p = .73, FET), AD/HD type (p = .70), or medication type (p = .06). No 
significant differences were evident regarding rates of Learning Disability Diagnosis 
(LD; p = .42, FET), Oppositional Defiant Disorder Diagnosis (ODD; p = .52, FET), or 
Conduct Disorder diagnosis (CD; p = .38, FET). Furthermore, no significant differences 
were evident regarding any of the academic variables including having failed a subject (p 
= .15, FET), having repeated a grade (p = .62, FET), history of being suspended (p = .46, 
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FET), history of psychological treatment (p = .10, FET), or rates of Individualized 
Education Plans (IEP; p = .06, FET). Taken together, these results indicate that the 
completers and non-completers did not differ in any significant ways. Thus, the children 
in the completers group are believed to be a good representation of typical children in the 
AD/HD population. 
Order Effects. Additional analyses were conducted to assess for the possibility of 
order effects. In particular, these analyses assessed whether the order of the child’s on-off 
medication sequence or the order of the IQ form had an effect on the findings. A 2 
(Medication Order) X 2 (Medication Status) repeated measures analyses of variance 
(ANOVA) revealed no significant interactions between the variables. Specifically, the 
interactions between medication order and medication status F(1, 32) = .15, p = .70) was 
not significant. The 2 (Form Order) X 2 (Medication Status) was also not significant, F(1, 
32) = .92, p = .35). Also of note, no significant main effects occurred due to the order of 
either variable (medication order; F(1, 32) = .16, p = .69; Form order, F(1, 32) = .00, p = 
.97). Since no order effects were observed, these variables were not included in any of the 
following analyses.  
Correlational Analyses. Correlational analyses were performed to assess the 
relationships between the IQ and CPT variables when the children were on and off 
medication. As shown in Tables 4 and 5, the four IQ indices were highly correlated with 
FSIQ across medication conditions. The correlations ranged from .50 to .80 and were 
significant regardless of medication status. Though the correlations between FSIQ and 
the VCI and PRI were similar to those reported for the normative sample, the correlations 
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between FSIQ and the WMI and PSI were somewhat lower.  
As seen in Table 5, the correlations for the IQ and CPT variables were non-
significant for all comparisons when the children were off medication. In contrast, when 
on medication, significant negative correlations were evident among many of the IQ and 
CPT variables. These correlations ranged from -.34 to -.50. For instance, small negative 
correlations were observed between FSIQ and the CPT variables of Omissions (-.38), Hit 
Reaction Time (-.34), Hit Rate Standard Error (-.38), and Variability (-.38). These 
findings indicate that when the children were medicated, a negative relationship was 
evident among IQ scores and CPT performance, whereby higher IQ scores were related 
to fewer errors on the CPT.   
Group-Based Analyses Of Medication Effects 
To test the effect of stimulant medication on the performance of children with 
AD/HD on the WISC-IV, a repeated measures analysis of variance (ANOVA) was 
performed for the FSIQ and Index scores. Mean scores and standard deviations for the on 
and off medication groups are presented in Table 6.  
FSIQ. The analyses revealed that the use of stimulant medication produced 
significant increases on many dimensions of the WISC-IV. As seen in Table 6, the use of 
stimulant medication resulted in a significant increase in the FSIQ score, F(1,34) = 26.12, 
p < .001. This increase in score was equivalent to approximately 7 points. The partial eta 
squared value was .44, which is considered a large magnitude of effect (Cohen, 1988). 
Thus, at a group-based level, affected children obtained higher FSIQ scores when 
medicated. 
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Indices. To explore what components of the WISC-IV were causing the increase 
in FSIQ, repeated measures ANOVAs were computed for each index score. These 
analyses revealed that the source of change seen in FSIQ scores was due to a significant 
effect of medication in performance on several of the index scores. Specifically, when on 
medication participants’ scores increased significantly on the VCI (F(1,34), = 11.62, p < 
.01), WMI (F(1, 4) = 6.40, p  < .05), and the PSI (F(1,34) = 7.35, p < .01). On average an 
increase in score of approximately 6 to 7 points was considered significant on these 
indices. The effect sizes as measured by partial eta squared ranged from .16 for the WMI, 
.18 for the PSI, and .26 for the VCI. No significant differences were seen for PRI scores, 
F(1,34) = 1.92, p = .18. These findings indicate that the change seen in FSIQ was most 
likely due to the combined impact of several indices.  
Individual-Based Analyses of Medication Effects 
The individual analyses of IQ test differences were computed using Jacobson and 
Truax’s Reliable Change Index (RCI), a statistical procedure used to determine whether 
clinically meaningful change has occurred as the result of the implementation of a 
treatment. It is calculated for each participant and corrects the change score between two 
points of assessment by the unreliability (test–retest reliability) of the instrument used to 
assess treatment effects. It is calculated by dividing the difference between the pre-
treatment and post-treatment scores by the standard error of the difference between the 
two scores. If the resulting RCI is greater than 1.96, then the difference is considered 
reliable—a change of this magnitude would not be expected due to chance findings.  
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For the purposes of this study, the RCIs were computed by subtracting the un-
medicated session IQ scores from the medicated session IQ scores. Thus, if a positive 
difference was noted, it would in the expected direction (IQ scores increase with the use 
of stimulant medication). Additionally, the RCIs were calculated using the normative 
population age and gender specific test information when available data from the WISC-
IV and CPT manuals. For instance, the CPT manual provided information on the standard 
error of difference statistic broken down by age groupings and gender, whereas the 
WISC-IV provided this information only specific to age groupings.  
RCIs were calculated for the FSIQ and each of the four indices. Once these scores 
were obtained, new categorical variables were created that identified each child as a 
responder or non-responder based on whether they exhibited a positive reliable change on 
each of the IQ variables. For instance, children demonstrating a reliable change on their 
FSIQ score were labeled FSIQ responders and coded a 1, while children who did not 
demonstrate a reliable change on FSIQ were labeled FSIQ non-responders and were 
coded with a 0. The percentage of children demonstrating reliable change (improvement) 
on FSIQ and the four indices is shown in Table 7.  
FSIQ. RCIs for the thirty-five participants ranged from –3.81 to 9.25 on the FSIQ. 
On average an improvement of 8 points on the FSIQ was considered a reliable change, a 
finding similar to that of the group-based analyses. Forty-eight percent of the children 
showed a significant positive change in FSIQ (M=1.97, SD= 2.28).  
Indices. RCIs for each of the indices ranged from -2.14 to 6.13 on the VCI, from  
-2.67 to 4.81 on the PRI, from -6.01 to 8.73 on the WMI, and from -3.13 to 4.13 on the 
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PSI. On average an increase of 11 points on the VCI, PRI, and WMI, and 14 points on the 
PSI constituted a reliable change in scores. Percentages for the four indices were 
somewhat smaller than that for the FSIQ, with 31% exhibiting reliable change on the 
VCI, 20% on the PRI, 46% on the WMI, and 29% on the PSI.  
Overall IQ Response. Given the importance of identifying the percentages of 
children who exhibited any significant improvements on the WISC-IV due to medication 
usage, counts of the children who showed a positive reliable change on any of the IQ 
scores were computed. These counts revealed that a total of 89% of children (N = 31) 
exhibited a reliable improvement in their scores on either the FSIQ or one of the four 
indices after taking their stimulant medication. Thus, the majority of children showed 
some kind of reliable increase in their scores on the WISC-IV due to medication use. 
Nonetheless, four children had no response on any of the five IQ variables, which 
suggests that just being on medication is not enough for some children to exhibit 
significant improvements in their IQ test performance. 
Check on Experimental Manipulation 
 As a check on whether the medication the children were taking was actually 
effective, additional group-based analyses were conducted. Specifically, repeated 
measures ANOVAs were conducted looking at the difference between the off medication 
and on medication testing results for each of the CPT variables. Results from this analysis 
revealed that when on medication, children showed significant differences in their 
performance on several of the CPT variables. As shown in Table 8, significant 
differences were noted on the AD/HD Clinical Confidence Index, F(1, 34) = 21.51, p < 
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.001. In particular, children with AD/HD were less likely to exhibit performance on the 
CPT that resembled that of a clinical AD/HD population. In addition, significant 
differences were also seen in Hit Reaction Time, F(1, 34) = 35.01, p < .001, Hit Reaction 
Time Standard Error, F(1, 34) = 24.39, p < .001, and on Variability, F(1, 34) = 14.92, p < 
.001. These results indicate that children with AD/HD had improved reaction times, 
exhibited less variability in their reaction times, and had less variability in their responses 
in general, after taking stimulant medication. Interestingly, no significant group-based 
differences emerged in regards to the number of commission, F(1, 34) = 1.39, p = .25, or 
omission errors, F(1, 34) = 3.18, p = .08, children made after taking medication. 
Because children exhibit individual differences in their response to stimulant 
medication, further analyses were conducted to identify which children were considered 
as having a positive response to their medication. This was achieved by computing RCIs 
for each child based on their performance on the CPT. Though scores on several CPT 
indices were recorded, only the Clinical Index, Commissions, Omissions, Hit Reaction 
Time scores, and Variability were used in calculating the RCIs. This decision was based 
upon information in the manual and research findings indicating that these variables are 
most sensitive to effects of medication, and these variables exhibit a moderate to high 
test-re-test reliability coefficient (Conners, 2000; Epstein et al. 2003; Riggio et al., 2001). 
Thus, if a child showed a positive reliable change of 1.96 or higher on any of these CPT 
indices, he/she was classified as a CPT medication responder. Children who did not show 
a reliable change on any of the aforementioned CPT variables were labeled CPT non-
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responders. Table 9 provides a breakdown of the percentages of children who showed a 
reliable change on each of the CPT variables. 
Based on the RCI results, 77.1% percent of children (N = 27) were labeled CPT 
medication responders, due to their having exhibited a reliable change on at least one of 
the CPT variables following the use of stimulant medication. The remaining eight 
children showed no significantly reliable differences in their scores on any of the five 
CPT variables. Thus, when using the CPT to assess medication efficacy, not all children 
in the sample were identified as being on a medication that seemed to effectively control 
their symptoms of AD/HD, particularly symptoms of inattention and impulsivity.  
CPT Medication Responder vs. Non-Responder Analyses 
 Given the findings regarding medication efficacy, analyses were conducted to 
assess for possible differences in IQ test performance between the groups of children 
labeled as CPT medication responders and non-responders. This was achieved using 2 
(CPT Medication Responder) x 2 (Medication Status) repeated measures ANOVAs.  
FSIQ. Analyses revealed a significant interaction between CPT medication 
response and medication status on FSIQ score, F(1, 33) = 4.22, p < .05. Specifically, 
FSIQ scores varied as a function of medication usage and response to the CPT. This 
difference was considered a noticeable effect based on the partial eta squared value of 
.11. A one-way ANOVA revealed that the significant difference between the groups of 
CPT medication responders and non-responders was on FSIQ score when on medication. 
In particular, when on medication, children labeled CPT medication responders obtained 
significantly higher FSIQ scores than non-responders, F(1, 33) = 5.45, p < .05. For CPT 
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medication responders the mean FSIQ score on medication was 107.6, (SD = 12.23) 
compared to 95.63 (SD = 14.31) for non-responders. Thus, it appears that children who 
exhibited a positive response to their medication as measured by CPT scores, obtained 
FSIQ scores when on medication that were approximately 12 points higher than those 
obtained by children whose medication was not as effective. A one-way ANOVA also 
showed that a significant difference emerged between groups in the amount of change 
that occurred in FSIQ scores due to medication usage, F(1, 33) = 4.22, p < .05). The 
mean score difference in FSIQ for CPT medication responders was 8.75 points (SD = 
8.17) compared to 2.13 (SD = 7.32) for non-responders. See Figure 4 for a summary of 
these differences.  
Indices. Repeated measures ANOVAs of group-based differences in index scores 
revealed that children who were effectively medicated scored higher only on one index. 
Scores for CPT medication responders and non-responders were different on the VCI 
following use of medication, F(1, 33) = 6.18, p < .05. The partial eta squared value for 
this effect was .16. A one-way ANOVA revealed that VCI scores obtained after taking 
medication were higher for CPT medication responders compared to non-responders, 
F(1, 33) = 5.49, p < .05. In fact, the CPT medication responders obtained a mean VCI 
score of 107.6 (SD = 14.19) compared to non-responders who obtained a mean score of 
94.3 (SD = 13.97). Interestingly, significant differences were also evident in the amount 
of change that occurred due to medication use, F(1, 33) = 6.18, p <. 05. The mean change 
in scores for CPT medication responders was approximately 8 points (SD = 9.35) 
compared to non-responders who exhibited a decrease in scores of 1.38 (SD = 7.35) when 
 49 
medicated. Thus, non-responders actually scored higher on the VCI when not medicated; 
however, these differences were not significant, F(1, 7) = .28, p = .61. This same pattern 
was evident regarding PRI scores for non-responders; yet the differences were not 
significant F(1, 7) = .71, p = .43). In sum, these analyses revealed that when taking a 
medication that effectively treats one’s symptoms, children with AD/HD score higher on 
the FSIQ and VCI. Moreover, their scores are significantly higher than children taking 
ineffective stimulant medication. 
Percentages of the CPT medication responders and non-responders who exhibited 
a reliable change in FSIQ and each of the indices were computed to compare with the 
previously obtained percentages (see Table 10). Analyses of the counts revealed results 
somewhat similar to those obtained using the entire sample. Specifically, 59% of CPT 
medication responders (N = 16) showed a reliable change in FSIQ compared to 12% of 
CPT non-responders (N = 1). On the VCI, 37% of CPT medication responders (N = 10) 
showed a reliable change compared to 12% of the non-responders (N = 1). On the PRI, 
26% of CPT medication responders (N = 7) showed a reliable changed while none of the 
non-responders evidenced an RCI of 1.96 or higher. On the WMI, 48% of CPT 
medication responders (N = 13) had reliable changes in scores compared to 38% of non-
responders (N = 3). And finally, on the PSI, 22% (N = 6) of children labeled as having a 
positive response to their medication showed a reliable change in scores compared to 
50% of non-responders (N = 4). Overall, the percentages for CPT medication responders 
were slightly larger than those based on all thirty-five children; however, two interesting 
findings emerged. First, the percentage of CPT medication responders who responded on 
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the PSI was smaller than that of the total sample, and second the number of non-
responders who exhibited a reliable change on the PSI was much higher than that of CPT 
medication responders. 
Exploratory Analyses 
 Additional analyses were conducted to assess for the presence of variables that 
could impact IQ test performance. The variables included in these analyses were gender, 
race, type of AD/HD (excluding the Hyperactive-Impulsive type), and type of stimulant 
medication (i.e. amphetamine-based medication compared to methylphenidate-based 
medication). Each of these variables were analyzed using 2 x 2 repeated-measures 
ANOVAs. The results revealed no significant interactions between gender and 
medication status, F(1, 33) = .52, p = .48) or race and medication status, F(1, 33) = .40, p 
= .53. The same was true for type of stimulant medication and medication status, F(1, 33) 
= .04, p = .85, and AD/HD type and medication status, F(1, 33) = .32, p = .58. However, 
the observed power for each of these analyses was extremely low, with rates ranging 
from .05 to .27, making it difficult to identify any possible differences. 
Interestingly, a main effect was found for gender, F(1, 33) = 7.12, p < .01. The 
partial eta squared for this effect was .18. Follow-up analyses revealed that females with 
AD/HD (M = 93.3, SD = 3.51) scored lower than males with AD/HD (M = 104.4, SD = 
2.22). In sum, though none of the variables appeared to have an impact on whether a 
child exhibited a reliable change in FSIQ due to medication use, there were significant 
differences between males and females regarding their FSIQ scores, with females with 
AD/HD generally having lower FSIQ scores than males with the disorder. 
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CHAPTER IV 
DISCUSSION 
 
 
 According to Barkley’s theory, children with AD/HD exhibit deficits in the 
processes that control and regulate thought and actions. These deficits cause impairments 
in executive functioning, which negatively impact an affected child’s ability to plan, 
organize, make decisions, problem-solve, and regulate their behavior. These executive 
functions, which have been identified by Cattell-Horn-Carroll’s theory (CHC) as 
components of the construct of intelligence, are commonly measured by intelligence tests 
such as the WISC-IV. Given this knowledge, it has generally been thought that children 
with AD/HD have lower IQs than children without the disorder. However, variability in 
research findings has made it difficult to reach an accurate conclusion regarding the 
intellectual functioning of affected children. A primary reason for such inconsistencies 
appears to be the failure to assess the effects of stimulant medication on test performance. 
Though stimulant medication has been shown to be the most efficacious treatment for 
AD/HD, few studies have focused on whether treatment with stimulants actually results 
in improvements in IQ scores. 
In an effort to help clarify this situation, the primary purpose of this study was to 
determine whether stimulant medications have a significant effect on the IQ test 
performance of children identified as having AD/HD. More specifically, it was proposed 
that children with rigorously defined AD/HD would exhibit significant increases in FSIQ 
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scores following a dose of their stimulant medication. Although it was believed that 
scores would be improved on all four indices, the WMI and PSI were expected to show 
the largest increases because of their relationship to the executive functions, proposed by 
Barkley, to be deficient in children with AD/HD. In addition, rather than assuming the 
children were taking a medication that was effectively treating their symptoms, analyses 
were conducted to assess medication efficacy and whether this had an effect on test 
performance. Accordingly, children who exhibited a positive response to medication 
were expected to exhibit larger increases in scores than those whose medication was not 
as effective in managing their symptoms. The final aim of this study was to clarify the 
relationship between group-based and individual-based analyses by conducting both 
types of analyses and making comparisons of the results.  
General Findings 
The results of the group-based findings were supportive of the first hypothesis. 
Analyses revealed that at a group-based level, a main effect for medication was present. 
Hence, after taking stimulant medication children with AD/HD obtained significantly 
higher IQ scores. Overall, children showed an improvement of about seven points on the 
FSIQ. This magnitude of change is equivalent to about half of a standard deviation on the 
WISC-IV and was considered strong, as evidenced by a partial eta squared effect size of 
.44.  
Regarding the changes in indices, the hypotheses were partly supported by the 
finding that children with AD/HD exhibited improved performance on three of the four 
indices. Affected children obtained significantly higher scores on the VCI, WMI, and PSI 
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following a dose of their stimulant medication, with the differences in scores averaging 
six to seven points higher on these indices. Though it was proposed that significant 
increases would occur on all of the indices as a result of medication usage, no significant 
changes were evident in regard to PRI scores. As expected the largest increases in scores 
occurred on the WMI and PSI. However, an interesting finding emerged, which indicated 
that though the improvements on the VCI were the smallest of the significant 
improvements, the VCI had a more noticeable effect. Specifically, the partial eta squared 
effect size of .26 indicates that approximately 26% of the total variability in VCI scores 
was attributable to the use of medication, compared to 16% and 18% for the WMI and 
PSI, respectively. This is an interesting finding in light of the fact that previous research 
has identified that stimulants have the strongest effects on tasks of working memory and 
speed of information processing (Kempton, et al., 1999; Mehta et al., 2004). Taken 
together, these findings imply that stimulants had a slightly stronger effect on tasks 
measuring verbal abilities, and that the increase seen in FSIQ was the result of a 
collection of changes instead of being attributable to one particular index.  
 As previously noted, another purpose of this study was to examine the results at 
both the group and individual levels. While most studies in the field have focused on 
group-based findings, it is not clear whether such findings are also applicable to 
individual children. Given the findings by Anastopoulos et al. (1994), it is plausible that 
individual children do not exhibit the same pattern of test scores as indicated by group 
averages. This can occur when a small number of subjects’ results are supplying the 
driving force behind the group-based findings.  
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 According to the results, the individual and group-based analyses were somewhat 
similar. In particular, both resulted in the finding that medication improves IQ test 
performance, and that this improvement was due to increased scores obtained on several 
indices. However, several differences emerged. First, though the FSIQ was shown to 
increase at the group level, only forty-eight percent of children had a reliable change in 
FSIQ. Secondly, according to the group-based analyses, the change seen in FSIQ was 
attributable to an improvement of about seven points on the VCI, WMI, and PSI. 
Conversely, at the individual level, a reliable change on these indices was equivalent to 
an increase of eleven to fourteen points. And, though forty-six percent of children 
demonstrated a reliable change on the WMI, only about a third of children showed a 
reliable change on the VCI and PSI. Such differences highlight the need for caution in 
interpreting group-based results and argue against a “one size fits all” approach. 
Given the MTA study (2004) findings showed that subjects who were treated by 
physicians in the community responded less favorably on outcome measures than those 
whose medication response was objectively assessed and titrated throughout the course of 
the study, analyses were conducted to assess medication efficacy. In particular, though 
the children in the community arm of the project exhibited significant improvements in 
their behavior in several domains, these improvements were not as great as those for the 
children in the medication management group. Therefore, rather than assume that 
participants’ were on an effective medication, analyses were conducted to examine each 
child’s response to their stimulant medication and to assess if differences in response 
rates produced variability in IQ test performance. This was accomplished by using the 
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RCI procedure developed by Jacobsen and Truax (1996) to identify the presence of 
reliable change on CPT scores due to medication response. According to these results, 
over three-quarters of children exhibited a positive reliable change on at least one of the 
CPT variables. Thus, many of the children were taking medication that was considered 
effective, as measured by their CPT responses.  
As expected, children who responded positively to medication obtained 
significantly higher IQ scores than those who did not respond to their medication. In fact, 
children taking an effective medication scored an average of twelve points higher on 
FSIQ than those whose medication was not effective. A similar finding was also noted 
for their scores on the VCI, which were thirteen points higher. Also, the amount of 
change between off and on FSIQ and VCI test scores for medication responders was 
significant, which was not the case for non-responders. In particular, responders showed 
an increase of eight points in FSIQ and VCI scores when on medication. These 
differences are almost equivalent to a full standard deviation on most intelligence tests 
used today. Such substantial differences bring to light the importance of assessing 
medication efficacy and appropriately titrating medication dosages.  
Interestingly, unlike the group-based analyses of all children in the study, no 
significant improvements were observed for the other indices. Thus, while stimulants 
have a general impact on working memory and speed of information processing, they 
appear to have a stronger impact on a child’s verbal abilities when appropriately 
prescribed and titrated. Hence, taking stimulant medication will indeed improve test 
performance yet, taking a medication that effectively manages a child’s symptoms results 
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in larger improvements in the abilities measured by IQ tests. 
Additional analyses were conducted to assess whether any particular variables had 
an effect on the main findings. Interestingly, a main effect was found for gender whereby 
girls scored lower on FSIQ than males. The mean difference in scores was approximately 
eleven points. Though there were only ten girls in the sample, the findings were robust. 
Rucklidge and Tannock (2001) also identified this difference in their study. This finding 
indicates the importance of assessing the impact of variables that could differentially 
affect the relationship between IQ test performance and stimulant medication usage. 
Though these findings suggest females with AD/HD are not as intelligent as males with 
the disorder, another reason may explain this finding. Since the criteria for AD/HD was 
based on the behavior of males, it seems females have to be more impaired in order to 
meet criteria for the diagnosis. By being more behaviorally impaired, one would expect 
significantly lower scores on other measures of functioning.  
No other variables, including race, stimulant medication type, or AD/HD type 
were found to have a significant effect on the findings. However, it should be noted that 
these analyses had insufficient power to adequately detect possible effects of these 
variables on the findings. Given the limited number of studies addressing this issue, 
future research will be key in elucidating the relationship between gender, stimulant 
medication, AD/HD, and IQ test performance. 
As previously mentioned, there has been a great deal of uncertainty about whether 
children with AD/HD have lower IQ scores than children in the general population. The 
findings from the current study are consistent with previous research indicating that the 
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IQs of children with AD/HD are normally distributed. Specifically, affected children 
were found to score in the average range when both on and off medication. However, 
when effectively medicated, their scores were in the upper end of the average range; but, 
when not medicated, their scores fell in the lower end of the average range. Therefore, 
depending on the state in which children are tested, their test performance could result in 
scores that fall in either the higher or lower ends of the average range like those of 
unaffected children. This finding might explain why affected children have exhibited 
lower scores in previous studies, especially in those studies that did not control for 
medication status prior to testing. For instance, previous studies indicating that children 
with AD/HD score between 7-15 points lower than unaffected children is possibly an 
artifact of the child’s medication usage and efficacy prior to testing.  
The present findings are also important in the context of the MTA findings. 
Specifically, the group-based analyses for the entire sample showed a significant amount 
of improvement in test performance when children were medicated. This finding is 
comparable to that of the results of the MTA community care group, who also exhibited 
significant improvements when medicated. However, the magnitude of the observed 
change for both this sample and the community care group was less than that of the group 
of children who were taking an effective medication, a group analogous to the medication 
management group. These findings emphasize that a prescription for a stimulant 
medication is not enough. Instead, children’s responses to medication must be objectively 
and routinely assessed, and the dose titrated accordingly. Otherwise, they are not 
receiving the full benefit of treatment. 
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 Another interesting finding from this study regards the magnitude of changes 
evident in the FSIQ and indices when medicated, especially on the FSIQ and VCI. In 
general, children showed significant increases in scores on the FSIQ that were attributed 
to improvements in indices measuring working memory, speed of information 
processing, and verbal comprehension. This is somewhat consistent with prior research; 
however, the significant increase in VCI scores was surprising, especially the magnitude 
of change in VCI for the medication responders.  
Several factors should help to explain these findings. First, the structure of the 
WISC-IV is much different than its predecessors, which have been used in past research 
to assess the intellectual functioning of children with AD/HD. One of the most important 
changes is in how the FSIQ is calculated. Specifically, rather than include only two of the 
four WMI and PSI subtests as on the WISC–III, all four of the WMI and PSI subtests are 
now included in determining FSIQ on the WISC-IV. Additionally, several of the indices 
have been refined so they are more representative of the Gf-Gc abilities as identified by 
CHC theory. For instance, the WMI now comprises only two subtests that are direct 
measures of working memory (Digit Span and Letter-Number Sequencing versus Digit 
Span and Arithmetic on the WISC–III FFD) and is no longer confounded by the inclusion 
of the Arithmetic subtest—a measure of math ability and fluid intelligence. Furthermore, 
the PRI now has only one timed visual-motor test (Block Design), in contrast to the three 
that were on the WISC-III. This change reflects the increased emphasis on fluid 
reasoning abilities and reduces the impact of speeded performance and motor skill on this 
index. Overall, these changes have improved the ability of the WISC-IV to assess both 
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fluid and crystallized intelligence. Furthermore, the inclusion of additional subtests that 
assess working memory and processing speed in the calculation of FSIQ should result in 
a higher FSIQ, given the improved performance on WMI and PSI that occurs as a result 
of stimulant medication use. 
In regard to the significant increase in VCI, it appears that children exhibited 
improvements in the executive function of reconstitution as a result of medication use. In 
particular, when on medication, especially one that was effective, children exhibited 
increased verbal fluency and application of knowledge. Verbal fluency is the ability to 
take apart incoming information and then use parts of this information or create new parts 
to produce a verbal or behavioral response. It is dependent on behavioral inhibition to 
provide the delay necessary for the individual to take time to process information from 
the situation, develop possible responses, and then test out these potential responses 
before selecting and engaging in one. This process was evident during testing sessions as 
noted by the fact that, when medicated, many children provided an improved response to 
verbal subtests. Specifically, their responses were more reflective of 2-point answers, 
more complex and conceptually correct responses, rather than vague or incomplete 
responses that were scored as 0 or 1 point. For instance, when off medication, children 
frequently responded to questions with “ums” and “uhs” while trying to describe 
concepts, or as soon as the question was posed, they quickly stated, “I don’t know.” Thus, 
it appears that stimulants provided the inhibition in responding needed to retrieve learned 
information, organize it, and then present it in a coherent manner. As has often been 
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reported about children with AD/HD, it is not their lack of knowledge that causes them 
problems but their difficulty accessing that knowledge when they need it.  
 Though one could speculate that stimulant medication would have a stronger 
impact on fluid intelligence given its dependence on the physiological structures that 
support intellectual behavior, it appears that medication improves crystallized abilities. 
This is supported not only by the aforementioned VCI findings but also by the fact that 
no significant changes were evident at a group-based or individual level on the PRI. Fluid 
intelligence is best measured by tasks requiring adaptation to new situations and those for 
which prior learning is not helpful. The subtests that comprise the PRI require children to 
solve novel tasks by forming and recognizing concepts, identifying and perceiving 
relationships, and drawing inferences. Given these abilities are direct measures of fluid 
intelligence and children did not exhibit significant changes in PRI scores when 
medicated, it appears fluid intelligence was not significantly affected by medication use. 
Implications  
The findings from this study have several implications for research, theory, and 
clinical practice. Since children with AD/HD were shown to exhibit significant increases 
in IQ scores as a function of stimulant medication use, researchers must begin to identify 
the medication status of children prior to testing. Furthermore, medication efficacy needs 
to be assessed, due to the fact that children who were effectively medicated obtained IQ 
scores of almost a full standard deviation higher than children who were not effectively 
medicated. As noted earlier, the variability in findings across studies seems strongly 
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related to the failure to assess both the effects of stimulant medication on IQ test 
performance and medication efficacy prior to testing.  
Moreover, the findings that the largest improvements in IQ scores were on 
measures of crystallized abilities suggest that AD/HD is a disorder of functional rather 
than structural deficits. Specifically, it appears the reason for children’s difficulties on an 
IQ test, among other things, is related to problems applying knowledge rather than one of 
structural deficits. Though some have theorized that the executive functions are closely 
related to fluid intelligence, children with AD/HD showed no changes when medicated 
on the PRI, which is a measure of fluid intelligence. Further research is needed to 
determine the direction of the relationships between these concepts and their theoretical 
and clinical implications. 
Another area that must be addressed in future studies is the need to examine 
differences at both the level of groups and individuals. This study, as well as the study by 
Anastopoulos et al. (1994), draws attention to this point. Children did not exhibit the 
same responses as those implicated by group analyses. In fact, it seemed that only a small 
percentage of children actually exhibited the same pattern of scores as suggested by the 
group-based findings. Response patterns and vital characteristics of individual children 
are often obscured by large group analyses, which was evident in this study. Thus, 
reliance on group-based averages may lead to erroneous conclusions. 
In practice, the question of whether children with AD/HD should take stimulant 
medication before undergoing a Learning Disability (LD) or Advanced Learner (AL) 
evaluation is often asked. Interestingly, many parents think their child should be on 
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medication for an AL evaluation because they believe this will help him perform “at his 
best.” On the other hand, when preparing for an LD evaluation, parents often choose to 
take their child off medication in order to demonstrate what their child’s functioning is 
“really like.” Based upon the findings of this study, the latter is not a good idea. In fact, 
being off medication will most likely make it more difficult to identify a learning 
disability. On average, children in this study exhibited a seven-point difference between 
their scores when tested off and on medication. This is an extremely significant finding 
when considered in the context of educational placement assessments. As mentioned 
earlier, this is equivalent to half of a standard deviation on the WISC-IV. Such a 
discrepancy could mean the difference between placing children in regular or advanced 
classes, or worse, placing them in remedial classes that impede them in reaching their 
true potential. 
Consequently, if children with AD/HD receive lower IQ scores because of poor 
test behavior due to the lack of medication rather than true cognitive ability, clinicians 
will have more difficultly identifying the presence of a learning disability. When 
clinicians use an artificially lower IQ score for comparisons, children with AD/HD will 
need to exhibit a higher degree of impairment on an achievement test to demonstrate the 
significant IQ-achievement discrepancies required to be diagnosed with a learning 
disability (LD). This suggests that children who need accommodations may not receive 
them because their scores will not reflect the required discrepancy necessary for LD 
classification. This can only add insult to injury, given many children with AD/HD 
already exhibit poor academic performance. 
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Limitations 
 Before concluding, several important limitations need to be discussed. First, the 
most obvious of these was the fact that this study did not use a double-blind placebo 
design, which would have been a more scientifically rigorous way of conducting this 
experiment to eliminate possible bias. However, the design of this study has ecological 
validity, thereby increasing the generalizability of the findings, given its similarity to the 
manner in which assessment and treatment are provided in the community. Secondly, the 
children in the study were taking different stimulant medications. Such differences could 
have affected test performance. Though we attempted to obviate this issue by 
categorizing each medication as either an amphetamine-based or methylphenidate-based 
product, several of the children were on newer medications that are hybrid versions of the 
older products. For instance, two children were on Vyvanse, a stimulant medication that 
consists of d-amphetamine coupled with the essential amino acid L-lysine, whereas two 
other children were taking Focalin XR, a Dexmethylphenidate product. These product 
formulations could potentially produce differential effects in their management of the 
symptoms of AD/HD, resulting in differences in performance on an IQ test.  
In addition, the short interval between testing sessions could have resulted in 
practice effects that muddied the waters regarding true test performance differences. Here 
again, attempts were made to reduce the amount of practice effects; however, this was not 
entirely possible without changing the structure of the test. Counterbalancing the order of 
medication status was used as a method for reducing this problem, which seemed 
effective given the children showed a significant change in the two indices despite having 
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already encountered the test material. Nonetheless, the effect of practice could have 
affected the results. 
Given that the participants were not naive to stimulant medication, the 
conclusions should be interpreted with caution when applying the findings to children 
who are just beginning to take stimulant medication. Specifically, though this study used 
a short interval between testing sessions, most of the children had been on their 
medication for at least two years. Thus, it is possible that changes have occurred in the 
structure or functioning of the frontal lobes as a result of long-term stimulant medication 
use.  
Another caveat that must be considered, is that the sample of children in this 
study appeared to be functioning at a higher level than those frequently found in a typical 
group of children with AD/HD. In particular, only a small number of children in the 
current study had been suspended, failed grades, or had been diagnosed with ODD or a 
learning disability. Thus, caution must be exercised when applying these findings to a 
more impaired group of children with AD/HD.  
Other limitations include having used one type of IQ test and the limited range in 
age of participants. Such differences may reduce the generalizeability of the findings. 
Moreover, though prior research has shown that several of the CPT indices are sensitive 
to the effects of medication, it is not considered the “gold standard” for assessing 
medication response or efficacy. And finally, the small sample size did not allow for 
secondary analyses to determine possible factors that may mediate a child’s response to 
stimulant medication.  
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Summary 
 Notwithstanding the limitations of this study, the findings demonstrate how 
stimulant medications can substantially affect children’s performance on tests of 
intellectual ability. Moreover, the importance of assessing medication efficacy was 
highlighted by the fact that children taking an effective medication scored higher than 
those who did not have a positive response to their medication. These findings need to be 
noted by clinicians who work with children with AD/HD, especially those who perform 
psychoeducational assessments. Otherwise, children may be labeled as below average or 
be overlooked to receive educational opportunities such as advanced learner placement. 
Finally, the design of the study resembled that of the community comparison 
group of the MTA study making the findings useful to "real-world" clinicians and 
families. In particular, all children had been evaluated at a community clinic and most of 
the children were receiving stimulant medication treatment from their primary care 
physician. Thus, the findings have important implications for primary care physicians 
regarding the need for assessing the efficacy of a child’s medication and titrating the dose 
accordingly. Without attention to such details, children with AD/HD will continue to be 
labeled as having lower IQs and possibly placed in classes that do not help them achieve 
up to their potential. 
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Table 1  
 
Definitions of the Second Stratum Abilities as Proposed by CHC Theory 
 
Broad Ability Definition 
Fluid 
Intelligence/Reasoning 
(Gf) 
The use of deliberate and controlled mental operations to solve 
novel problems (i.e. tasks that cannot be performed automatically). 
It includes mental operations such as drawing inferences, concept 
formation, generating and testing hypotheses, identifying relations, 
problem-solving, and transforming information. Inductive and 
deductive reasoning are hallmark indicators of Gf. 
Crystallized 
Intelligence/Knowledge 
(Gc) 
The intelligence of the culture; it represents the acquired knowledge 
of the language, information and concepts of a specific culture, 
and/or the application of this knowledge. It is acquired during 
formal and informal education and general life experiences. 
Visual-Spatial Abilities 
(Gv) 
The ability to generate, retain, retrieve, and transform well-
structured visual images. This domain represents a collection of 
abilities that emphasize a different process involved in the 
generation, storage, retrieval, and transformation of visual images. 
Auditory Processing 
(ga) 
Abilities that depend on sound as input and on the functioning of an 
individuals hearing apparatus (i.e. the ear) 
Short-term Memory 
(gsm) 
The ability to apprehend and maintain awareness of elements of 
information in the immediate situation. A limited capacity system 
that loses information quickly through the decay of memory traces, 
unless an individual activates other cognitive resources to maintain 
the information in immediate awareness.  
Long-term Storage and 
Retrieval (glr) 
The ability to store and consolidate new information in long-term 
memory and later retrieve it through association.  
Cognitive Processing 
speed (gs) 
The ability to automatically and fluently perform relatively easy or 
over-learned cognitive tasks, especially when high mental 
efficiency such as attention and concentration is required. 
Quantitative knowledge 
(gq) 
Acquired store of declarative and procedural quantitative 
knowledge. It represents an individual’s store of acquired 
mathematical knowledge, which does not include reasoning with 
this knowledge. It is largely acquired through formal education. 
Reading/Writing (grw) A person’s breadth and depth of acquired store of declarative and 
procedural reading and writing skills. It includes basic reading 
skills and ability to read and write complex discourse. 
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Table 3  
Sample Characteristics 
 
Sample Size            N = 35 
Age              10.9 (SD = 1.6) 
Gender 
 Male      25  (71.4%) 
 Female      10  (28.6%) 
Race 
 Caucasian     31  (88.6%) 
 African American      4  (11.4%)  
 
AD/HD Diagnosis     
 Combined Type    20  (57.1%) 
 Inattentive Type    12  (34.3%) 
 Hyperactive-Impulsive Type     3    (8.6%) 
 
Other Diagnoses 
 Learning Disability      8  (22.9%) 
Oppositional Defiant Disorder       2    (5.7%) 
Conduct Disorder      1    (2.9%) 
 
Medication Type 
 Adderall XR       9  (25.7%) 
Concerta     13  (37.1%) 
 Ritalin LA       4  (11.4%) 
 Metadate       3    (8.6%) 
 Focalin XR       2    (5.7%)  
 Daytrana       2    (5.7%) 
Vyvanse       2    (5.7%)     
 
     M     (SD) 
ADHD Rating Scale Scores 
 Inattention symptoms                7.3     (2.3) 
 Hyperactive-Impulsive symptoms                   5.2     (3.0) 
 Inattention severity             20.3     (5.7) 
 Hyperactive-Impulsive severity            15.1     (6.9) 
 
BASC-2 T-scores 
 Inattention                66.5      (7.5) 
 Hyperactivity                            64.7     (12.5) 
 
Time on Stimulant (in months)                             30      (23.8) 
Time between Testing Sessions (in days)               25      (34.2) 
 
Note. BASC-2 = Behavior Assessment System for Children – Second Edition. 
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Table 6 
 
IQ Scores On and Off Medication 
 
 
       On Meds      Off Meds     ηp2   
 
         M   (SD)     M   (SD) 
FSIQ 104.8  (13.5)   97.6 (12.0)*** .44 
 
Index Scores 
VCI 104.5 (15.1)   99.0 (13.2)** .26 
PRI 106.3 (16.0) 103.7 (13.2) .05 
WMI 106.7 (14.2)   99.4 (14.7)* .16 
PSI   93.6 (12.6)   87.7 (14.5)** .18 
 
Subtest Scores 
BD 11.4 (3.7) 10.3 (3.4)* .12 
SIM 11.2 (3.3) 10.4 (2.9) .06 
DS   9.2 (2.7)   9.2 (3.1) .00 
PC 10.0 (4.0) 10.9 (3.1) .07 
CD   8.7 (3.0)   7.7 (3.1)* .15 
VOC 11.2 (2.9) 10.1 (2.8)*** .29 
LNS 13.4 (3.7) 10.8 (3.9)** .23 
MR 11.5 (3.6) 10.6 (2.7) .08 
COMP 10.3 (3.0)   9.3 (3.0)* .10 
SS   9.1 (2.1)   7.9 (2.8)* .14 
 
Note. FSIQ = Full Scale Intelligence Quotient; VCI = Verbal Comprehension Index; PRI 
= Perceptual Reasoning Index; WMI = Working Memory Index; PSI = Processing Speed 
Index; BD = Block Design; SIM = Similarities; DS = Digit Span; PC = Picture 
Completion; CD = Coding; VOC = Vocabulary; LNS = Letter-Number Sequencing; MR 
= Matrix Reasoning; COMP = Comprehension; SS = Symbol Search;  
*p < .05, **p < .01, ***p < .001. 
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Table 7  
 
Number of Children Showing Reliable Change on IQ Variables  
 
     
      Total with RC    Total without RC    
  
FSIQ 17 (49%)  18 (51%) 
 
Index Scores 
VCI  11 (31%)    24 (69%) 
PRI    7 (20%)    28 (80%) 
WMI  16 (46%)    19 (54%) 
PSI 10 (29%)  25 (71%) 
 
Note. RC = Reliable Change; FSIQ = Full Scale Intelligence Quotient; VCI = Verbal 
Comprehension Index; PRI = Perceptual Reasoning Index; WMI = Working Memory 
Index; PSI = Processing Speed Index. 
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Table 8 
CPT Scores On and Off Medication 
 
 
    On Meds                 Off Meds  
 
    Mean       SD        Mean       SD            F          p       ηp2 
 
Omissions   53.6    17.1         59.6        20.2   3.18      .08       .09 
Commissions   49.9      9.1         51.9          9.2   1.39      .25          .04  
Variability   51.5    11.9          58.0        11.3      14.92     .001***   .31 
Hit Reaction Time  45.1    10.6         54.1        14.2      35.03     .001***   .52 
HRT Standard Error       50.8        11.8         58.9        12.1      24.39     .001***   .43 
Confidence Index  49.7    24.1         66.0        24.5      21.51     .001***   .39 
 
Note. CPT= Conners Continuous Performance Task; HRT = Hit Reaction Time; *p < .05, 
** p < .01, ***p < .001. 
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Table 9 
Number of Children Showing Reliable Change on CPT Variables  
 
    
        Total with RC      Total without RC 
 
Omissions 13 (37%)  22 (63%) 
Commissions   1   (3%) 34 (97%) 
Variability 25 (71%) 10 (29%) 
Hit Reaction Time   1   (3%) 34 (97%) 
HRT Standard Error 13 (37%) 22 (63%) 
Confidence Index 16 (46%) 19 (54%) 
   
 
Note. CPT = Conners Continuous Performance Task; RC = Reliable Change; HRT = Hit 
Reaction Time. 
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Table 10 
 
Rates of Reliable Change in IQ Scores Based on Medication Response 
FSIQ Response  
  
  Reliable Change No Change 
Responder 16 (59%) 11 (41%) CPT 
Medication 
Response  Non-Responder 1 (12%) 7 (88%) 
 
 
VCI Response 
 
Reliable Change No Change 
Responder 10 (37%)  17 (71%) CPT 
Medication 
Response  Non-Responder 1 (12%) 7 (88%) 
 
 
PRI Response 
 
Reliable Change No Change 
Responder 7 (26%) 20 (74%) CPT 
Medication 
Response  Non-Responder 0 8 (100%) 
 
 
WMI Response 
 
Reliable Change No Change 
Responder 13 (48%) 14 (52%)  CPT 
Medication 
Response  Non-Responder 3 (38%) 5 (62%) 
 
 
PSI Response 
 
Reliable Change No Change 
Responder 6 (22%) 21 (78%) CPT 
Medication 
Response  Non-Responder 4 (50%) 4 (50%) 
 
Note. CPT = Continuous Performance Test; FSIQ = Full Scale Intelligence Quotient; VCI = Verbal 
Comprehension Index; PRI = Perceptual Reasoning Index; WMI = Working Memory Index; PSI = 
Processing Speed Index.
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Figure 4. Mean FSIQ Scores of CPT Medication Responders and Non-Responders When 
On and Off Medication 
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THE UNIVERSITY OF NORTH CAROLINA  
GREENSBORO 
 
CONSENT TO ACT AS A HUMAN PARTICIPANT 
 
Form for Parents/Guardians of Child Participants 
 
 
Project Title:  An Examination of the Effects of Stimulant Medication on the IQ Test       
                       Performance of Children with AD/HD 
Project Directors:  Jennifer Smith Adams, M.A. and Arthur D. Anastopoulos, Ph.D. 
 
Parent/Guardian’s Name: ___________________________________________ 
 
Participant's Name: ________________________________________________ 
 
DESCRIPTION AND EXPLANATION OF PROCEDURES: 
You and your child are being asked to participate in a project that will examine how stimulant 
medication affects your child’s performance on an intelligence test. Participation will involve 
having both you and your child complete various tasks that will take a total of approximately two 
to three hours of time.  
 
Your child will be asked to complete an intelligence test and a computerized attention task during 
two separate testing sessions that will take place approximately two weeks apart. During one of 
the testing sessions your child will be required to be on his/her stimulant medication for testing 
whereas during the other session, your child will be required to be off his/her stimulant 
medication. Each testing session will be videotaped and should last about one hour. Your child 
will have the option to discontinue participation at any time. 
 
This research project also requires you to complete an interview and several questionnaires about 
your child’s AD/HD symptoms and level of functioning in various settings. These questionnaires 
and interview should take about an hour to complete. Participation also includes having your 
child’s physician and teacher complete a few questionnaires. In particular, you will be asked to 
provide consent to speak with your child’s physician in order to obtain medical clearance for your 
child to participate in the study. Your child’s physician will also be asked questions regarding 
your child’s prescription. To gain information about your child’s academic functioning, one of 
your child’s teachers will be requested to complete a few questionnaires.  
 
RISKS AND DISCOMFORTS: 
The risks involved in this study are minimal and are no more than those usually associated with 
psychological testing. For instance, your child may feel mildly uncomfortable during the testing 
session where he/she is required to be off his/her medication. However, any distress your child 
may feel is not likely to be any greater than that experienced at other times your child is off 
medication. Furthermore, in order to ensure that your child is less likely to experience an adverse 
reaction to being off his/her medication, your child’s physician will be consulted to determine if 
your child can participate in the study. 
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Your participation in the project is entirely voluntary and, should you or your child become 
uncomfortable or distressed, you are free to refrain from answering any questions and withdraw 
from the study altogether at any point without penalty or prejudice. You and your child are also 
free to obtain information about this study from the researcher or researcher assistant running this 
study before, during or after your participation in this project. 
 
All information provided by you and your child will be kept confidential. All data will be 
identified by research numbers only and no individual's name will be directly associated with the 
data. Data will be kept in a locked file cabinet in a locked office building and destroyed after 5 
years. 
 
The principal investigator and research assistants involved in the study are required to sign 
confidentiality agreements. Only the principal investigator and research assistants who have 
signed confidentiality agreements will handle completed materials. All the information that you 
provide and all the information that you answer during the course of this project will be kept in 
strict confidentiality. 
 
BENEFITS: 
For participation in this study, your child will be paid $40 and you will be mailed a letter 
describing the results from your child’s testing sessions. You and your child will also benefit 
from a better understanding of issues related to psychological research and will have an 
opportunity to learn more about yourselves through responses to questionnaires and completion 
of an IQ test. Broader benefits will enable researchers and clinicians to better understand the 
effects of stimulant medication on children’s intelligence test performance. This research can aid 
in determining whether children with AD/HD should be on or off their medication prior to taking 
tests.  
 
CONSENT:   
By signing this consent form, you agree that you understand the procedures and any risks and 
benefits involved in this research. You and your child are free to refuse to participate or to 
withdraw your consent to participate in this research at any time without penalty or prejudice; 
your participation is entirely voluntary. Your privacy will be protected because you will not be 
identified by name as a participant in this project. 
 
The research and this consent form have been approved by the University of North Carolina at 
Greensboro Institutional Review Board, which ensures that research involving people follows 
federal regulations. Questions regarding your rights as a participant in this project can be 
answered by calling Mr. Eric Allen at (336) 256-1482. Questions regarding the research itself will 
be answered by calling Jennifer Smith Adams at (336) 256-0061 or Arthur D. Anastopoulos at 
(336) 346-3196 extension 303. Any new information that develops during the project will be 
provided to you if the information might affect your willingness to continue participation in the 
project. 
 
By signing this form, you are agreeing to participate and to allow your child to participate in the 
project described to you by Jennifer Smith Adams. 
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____________________________________   ______________ 
Participant’s Signature*       Date  
 
*If the participant is a minor or for some other reason unable to provide Informed Consent, 
complete the following: 
 
Participant is 
 
 years old or unable to sign because . 
 
________________________________  _________________________   
Custodial Parent(s)/Guardian Signature(s)  Date  
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THE UNIVERSITY OF NORTH CAROLINA  
GREENSBORO 
 
CHILDREN’S ASSENT FORM 
 
 
 
Many children with AD/HD take medication because it helps them pay attention and sit still in 
class. However, one thing we do not know very much about is whether medication helps children 
with AD/HD make better grades on tests. We are asking you to help us find out how the 
medication you take affects how well you do on different kinds of tests. 
 
If you agree to be in our study, we are going to ask you to complete a few tests. One of these tests 
is completed on a computer and measures how well you pay attention to things. The other test 
measures things like how many words you know and how fast you can memorize a code. 
 
If at any time you decide not to finish, you may stop whenever you want. You can ask questions 
at any time that you might have about this study. Also, your participation in this study is 
completely voluntary.  
 
Signing this paper means that you have read this or had it read to you and that you want to be in 
the study. If you don’t want to be in the study, don’t sign the paper. Remember, being in the study 
is up to you, and no one will be mad if you don’t sign this paper or even if you change your mind 
later. 
 
 
 
Signature of Participant _____________________________ Date ___________________ 
 
 
 
Signature of Investigator ____________________________ Date ___________________ 
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MEASURES 
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Participant Information Questionnaire 
 
 
I. CLIENT DATA 
Child’s Full Name:  ______________________     Parent’s Name: ____________________         
 
Age: ___________________                                   Date of Birth: _____________________ 
 
Gender: ________________       Ethnicity: ________________________ 
 
 
II. SCHOOL HISTORY 
Preschool Experience 
Has your child ever attended: No Yes 
Early Intervention Program   
Developmental Preschool   
Special Education Preschool   
 
 
School Performance and Behavior 
Has your child ever: No Yes 
Undergone testing   
Had an IEP or SPED   
Been labeled LD (Learning Disabled)   
Failed a subject   
Repeated a grade   
Been suspended   
Been expelled   
 
 
C. Special Services at School 
Has your child ever received: No Yes 
Resource room (part time)   
Self-contained LD room (full time)   
Behavior Disorders classroom (BED)   
Speech/Language Therapy   
Physical/Occupational Therapy   
School counseling   
Advanced Learner (AL)   
Classroom accommodations    
 
Current Grade Level: _______     Has IEP or receiving Special Education services:   Y      N 
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III. CHILD’S PSYCHIATRIC STATUS 
Has your child ever been diagnosed with: No Yes 
AD/HD  
 
  
Oppositional Defiant Disorder 
 
  
Conduct Disorder 
 
  
Antisocial Behavior 
 
  
Learning Disability 
 
  
Mental Retardation 
 
  
Schizophrenia/Psychosis 
 
  
Bipolar/Manic Depression 
 
  
Depression/Suicide 
 
  
Anxiety Disorders 
 
  
Phobias 
 
  
Tics/Tourettes 
 
  
Seizures/Epilepsy 
 
  
 
 
Has your child ever exhibited: No Yes 
Loose thinking   
Delusions   
Hallucinations   
Diminished interest in peers   
Self-injurious behavior   
Self-stimulation   
Alcohol use    
Cigarette use   
Substance use   
Physical abuse   
Sexual abuse   
 
 
Has your child ever been: No Yes 
Physically abused   
Sexually abused   
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IV. CHILD’S EVALUATION AND TREATMENT HISTORY 
 
A. Prior Evaluations 
Has your child ever undergone: No Yes (Date of evaluation) 
Psychological or Psychiatric Evaluation   
Pediatric evaluation for AD/HD   
Neurological Evaluation   
Intelligence Testing    
Academic Achievement Testing   
Speech/Language/Hearing Evaluation   
 
Results/Scores: 
 
 
 
Previous Diagnosis(es): 
 
 
 
Current Diagnosis(es):  
 
 
B. Psychological/Psychiatric Treatment 
 
C. Pharmacotherapy 
Has your child ever taken: NO Yes  
Ritalin    
Ritalin LA or SR   
Focalin   
Concerta   
Metadate ER or CD   
Adderall   
Adderall XR   
Dexedrine   
Dexedrine Spansules   
Cylert   
Clonidine/Tenex   
Wellbutrin   
Straterra   
 
Has your child ever received: No Yes (Date of Treatment) 
Counseling/Therapy   
Inpatient Treatment   
Residential Treatment (i.e. group home)   
Social Skills Training   
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D.  Current medication 
Name of your child’s physician: __________________________ 
 
Prescribed Stimulant Medication: _________________________  Dosage: _________________ 
 
Physician’s orders regarding this medication (i.e. take one pill 1 time each day in the morning): 
_____________________________________________________________________________  
 
Who administers this medication to your child: _______________________________________ 
 
Time(s) medicine is taken: _________________   # of days a week medicine is taken: _______ 
 
Is medication taken on the weekends?  Y    N       Is medication taken during the summer?  Y    N 
 
How long has your child been taking this medication? __________________________________ 
 
Does this child take any other medications? If so, please complete the following information. 
 
Medication: ___________________________   Dosage: __________   Reason: ____________ 
 
Medication: ___________________________   Dosage: __________   Reason: ____________ 
 
Medication: ___________________________   Dosage: __________   Reason: ____________ 
 
Please circle the number that best describes your perceptions regarding the efficacy of your 
child’s stimulant medication in managing his/her symptoms of AD/HD. 
 
 1  2 3    4 5 
 Not Effective           Somewhat Effective        Extremely Effective 
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THE UNIVERSITY OF NORTH CAROLINA  
GREENSBORO 
 
AD/HD Clinic 
 
 
Dear Doctor: 
 
Your patient _____________________________________ wishes to take part in a research study 
assessing the effects of stimulant medication on IQ test performance. I am conducting this study 
to fulfill the requirements for the doctoral degree in clinical psychology at UNCG. My faculty 
sponsor for the project is Dr. Arthur Anastopoulos of the UNCG AD/HD Clinic. The study will 
involve having children aged 8-12 who have been diagnosed with AD/HD take an IQ test and a 
computerized measure of attention during two separate testing sessions. For one of these testing 
sessions the child will be required to be off his/her medication during testing whereas for the 
other session the child will take his/her medication approximately 90-120 minutes before testing. 
The testing sessions will be held approximately 2 weeks apart. Statistical analyses will be 
conducted to determine whether participants’ stimulant medication affected their IQ test 
performance. 
 
Included with this letter you will find a consent form authorizing us to request and disclose 
information about this patient. The parent/legal guardian of your patient has signed this form 
because they would like me to request your approval for their child to participate in the 
aforementioned study. Basically, I need to make sure that it will be okay for your patient to be off 
his/her stimulant medication for one of the testing sessions. 
 
Attached you will find a form requesting your approval for your patient to participate in this 
study. Please complete part 1 of the form by indicating your recommendations regarding your 
patient’s request to participate in this study. If you feel that your patient can participate in this 
study please complete part 2 of the form. Once the form is complete, please return it in the 
postage-paid envelope included in this packet or feel free to the fax the form addressed to my 
attention to 346-3197. 
 
Thank you for your time regarding this matter. If you have any questions about the study please 
feel free to contact me at 256-0061 or my faculty sponsor, Arthur D. Anastopoulos, at 346-3196, 
extension 303. 
 
 
Sincerely, 
 
 
 
Jennifer Smith Adams, M.A.    Arthur D. Anastopoulos, Ph.D. 
Principal Investigator     Faculty Sponsor 
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Child’s name: _______________________________ Birth date: _________________ 
 
PART ONE:  Physician's Recommendations 
Please check the box that reflects your decision regarding whether you patient should be allowed 
to participate in the aforementioned study. 
 
 I approve my patient’s participation in this study. 
  
 I recommend that my patient NOT participate in this study. 
 
__________________________________________  _______________________ 
Physician's signature       Date 
 
__________________________________________  _______________________ 
Physician's name (print)       Phone    
 
__________________________________________   
Address           
 
__________________________________________   
City, State & Zip          
   
PART TWO:  Medication Information 
Please answer each question as it pertains to your patient. 
 
Patient’s Diagnosis(es): 
 
 
Prescribed Stimulant Medication: _______________________   Dosage: ___________________ 
 
Time(s) medicine is taken: ________________   # of days a week medicine is taken: __________ 
 
Is medication taken on the weekends?   Y    N     Is medication taken during the summer?   Y    N 
 
Does this child take any other medications? If so, please complete the following information. 
 
Medication: __________________________   Dosage: __________   Reason: _____________ 
 
Medication: __________________________   Dosage: __________   Reason: _____________ 
 
Medication: __________________________   Dosage: __________   Reason: _____________ 
 
Please circle the number that best describes your perceptions regarding the efficacy of your 
patient’s stimulant medication in managing his/her symptoms of AD/HD. 
 
 1  2 3    4 5 
 Not Effective           Somewhat Effective        Extremely Effective 
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APPENDIX E 
PARENT FEEDBACK LETTER 
 
 
 
 110 
SUMMARY OF CHILD IQ ASSESSMENT RESULTS 
 
Child’s Name:   
Examiner:               Jennifer Smith Adams, M.A. 
Dates of Testing:     OFF Medication: ______; ON Medication: ______   
Test Administered: Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV) 
 
 
 
Testing results obtained using a non-standardized format of an IQ test may not be an accurate 
estimate of your child’s true ability or intellectual functioning. Moreover, your child’s 
performance in a research setting may not be a strong indicator of his performance in other 
settings such as the classroom. Therefore, these results should not be used for clinical 
management or educational placement purposes.  
 
Keeping these limitations in mind, parents and teachers may want to consider the implications of 
the results. Based on your child’s performance, his scores significantly improved when he was on 
medication, especially in relation to his working memory and ability to process new information 
quickly. As seen in the above table, his scores on 8 of 10 subtests were better when he was on 
medication, which resulted in a 17-point increase in his Full Scale IQ score. In addition, your 
child’s behavior improved when he was on medication as evidenced by his increased 
concentration and attention span, his ability to sit still, and his completion of more items with 
fewer mistakes. Overall, your child appears to perform better when on medication in a testing 
situation such as taking an IQ test.  
Standard Score 
 
OFF 
Medication 
ON 
Medication 
Similarities 12 11 
Vocabulary 10 12 
Comprehension  11 15 
Verbal Comprehension Index 104 114 
   
Block Design  12 12 
Picture Concepts 13 17 
Matrix Reasoning 14 15 
Perceptual Reasoning Index 119 129 
   
Digit Span 11 13 
Letter-Number Sequencing 10 16 
Working Memory Index 102 126 
   
Coding 12 13 
Symbol Search 12 15 
Processing Speed Index 112 123 
   
FULL SCALE IQ (FSIQ) 113 130 
